2014 Reporting Requirements

2014 FCDS Annual Meeting Highlights

2014-2015 FCDS Webcast Series

Steven Peace, CTR
August 21, 2014
Day 1
- All the Slides/Handouts/PDFs from the Annual Meeting in one zip file
- Agenda
- Welcome to the FCDS Annual Meeting
- FCDS Updates - State of the State, Dr. Jill MacKinnon, Slides, Recording
- Cancer Data Uses and Dissemination, Joseph Lowry, MPH, Slides, Recording
- Individual and Neighborhood-Level Predictors of Mortality In Florida Colorectal Cancer Patients, Dr. David Lee, Slides, Recording
- Patterns of Care - Initial Assessment of Adherence to Evidence-Based Cancer Treatment Guidelines - Colon, Dr. Monique Hernandez and Judy Bonner, MSN, CTR, Slides, Recording
- SART Data Linkage, Brad Wahler, Slides, Recording
- Highlights from the NAACCR 2014 Annual Conference, Dr. Jill MacKinnon, Slides, Recording
- Update on Meaningful Use Stage II and CDA Validation, Dr. Monique Hernandez, Slides, Recording
- Data Acquisition Update, Mike Thiry, Slides, Recording
- Transition from CSV2 to Direct-Coded TNM and Summary Stage, Dr. Jill MacKinnon, Recording only, no slides with this session
- 2014 Reporting Requirements - 2014 FCDS DAM Highlights, Steve Peace, Slides, Recording
- 2014-2015 FCDS Education and Training Plan, Steve Peace, Slides, Recording
- Physician Claims and Treatment Data Validation Study, Dr. Monique Hernandez, Slides, Recording
- Introducing the FCDS IDEA Follow-Up System, Gary Levin, Kelly King, CTR, Cleveland Clinic, Sara Holton, CTR, Mayo Clinic, Slides, Slides (Sara Holton), Recording
- 2014 FCDS Data Validation Audit - 2012 Dx, Steve Peace, Slides, Recording
- Joan Byers Award Presentation, Mike Thiry, Slides, Recording
- The FCDS Annual Meeting of the Future and Round Table Discussion, Dr. Jill MacKinnon, Slides, Recording

Day 2
- 2013 FCDS QC Activities Summary, Steve Peace, Slides, Recording
- 2014 Grade Coding Instructions and ICD-O-3 Updates, Steve Peace, Slides, Recording
- 2014 Hematopoietic Rules and Data Base Updates, Steve Peace, Slides, Recording
- Coding Instructions for Surgery Fields Including Scope Rag LN, Steve Peace, Slides, Recording
- Reuting Issues and Problem Areas for Florida Registrars, Steve Peace, Slides, Recording
- Recent Developments in Cancer Diagnosis and Treatment, Steve Peace, Slides, Recording

Handouts
- Cancer Surveillance Community Timeline As of June 9, 2014
- Collaborative Stage Data Collection System Coding Instructions
- Installation Instructions Collaborative Stage Coding Instructions v02.05
- Free TNM 7th Edition Webinar Series Recordings and Other Resources
- FCDS Data Quality Indicator Report
- Guidelines for ICD-O-3 update implementation Effective January 1, 2014
- Users Guide for NCI’s Online Hematopoietic and Lymphoid Database
- Instructions for Coding Grade for 2014+ FCDS DAM LVI Errata
- Scope of Regional Lymph Node Surgery: A review of Data Validity, Revised Coding Directives, and Agency Transition Plans
State of the State
Florida Cancer Data System
2013-2014

Jill A. MacKinnon, PhD, CTR
Epidemiologist and Project Director
Certification

- Florida is NAACCR Gold Certified for the 11\textsuperscript{th} consecutive year
  - Confers assurance of data completeness and quality
  - A central registry meets or exceeds the minimum data quality standard as established by the Cancer Surveillance Community
Cancer Data Uses and Dissemination

Joseph Lowry, MPH
Chronic Disease Epidemiologist
Bureau of Epidemiology
Florida Department of Health
July 24, 2014
Presentation Outline

• Introduction

• Florida Cervical Cancer Special Topic Report

• Female Breast Cancer in Florida, 2010

• Late-Stage Breast and Colorectal Cancer Maps
The Role of Socioeconomic Status and Colorectal Cancer Risk in Florida

DJ Lee, R Sherman, M Hernandez, J MacKinnon and many others!
Characterize communities at risk for late-stage CRC

Evaluate demographic & screening correlates that predict a case being diagnosed in a cluster (1996-2010 cases)

- Individual-level Predictors:
  - Age, sex, insurance type from registry data
- Tract-level Predictors:
  - American Community Survey (06-10)
  - Poverty, education, language, nativity, racial/ethnic segregation
- County-level Predictors:
  - BRFSS (2010)
    - Screening FOBT, sig/colonoscopy
SES Predictors of CRC Mortality

Data linkage study with FDCS, ACHA, and Census information

- ~48,000 CRC cases diagnosed between 2007-2011
- Cox hazard regression models were fitted with candidate predictors of CRC survival and stratified by age group (18-49, 50-64, 65+)
Next Steps

- NCHS Report in press
- Need to create an infrastructure leading to a national consortium
- Just obtained NCI funding to support these efforts

<table>
<thead>
<tr>
<th>Estimated Cases from Nationwide linkage</th>
<th>Cancer Diagnosed Prior to NHIS Interview (Prevalent Cases)</th>
<th>Cancer Diagnosed Subsequent to NHIS Interview (Incident Cases)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6,167</td>
<td>15,767</td>
<td></td>
</tr>
<tr>
<td>6,550</td>
<td>16,567</td>
<td></td>
</tr>
<tr>
<td>1,533</td>
<td>15,000</td>
<td></td>
</tr>
<tr>
<td>3,717</td>
<td>11,300</td>
<td></td>
</tr>
<tr>
<td>1,900</td>
<td>5267</td>
<td></td>
</tr>
<tr>
<td><strong>28,000</strong></td>
<td><strong>96,717</strong></td>
<td></td>
</tr>
</tbody>
</table>
Patterns of Care in Colon Cancer (2010-2012)

Florida Cancer Data Compliance with NCCN Guidelines

FCDS Annual Meeting
July 24-25, 2014
Caribe Royale Resort
Orlando, Florida
Goals

- Capture baseline treatment patterns for colon cancer from FCDS data
- Analyze treatment delivered to assess compliance with NCCN guidelines
- Describe treatment by demographic and comorbid status
- Identify areas for targeted quality control review
Methods

- Select 2010, 2011, and 2012 colon cancer cases in FCDS database using defined inclusion criteria
- Separate cases by AJCC group stage
- Analyze each stage group’s cases according to recommended treatment for that stage as defined by NCCN guidelines
- Treatments reviewed included surgery, chemotherapy, and radiation
- Elixhauser comorbidity index created from AHCA
- Computer algorithm developed to process cases
# Methods

## NCCN Guidelines Version 3.2014

### Colon Cancer

<table>
<thead>
<tr>
<th>PATHOLOGIC STAGE</th>
<th>ADJUVANT THERAPY</th>
<th>SURVEILLANCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tis, T1, N0, M0</td>
<td>None</td>
<td>Colonoscopy at 1 y</td>
</tr>
<tr>
<td>T2, N0, M0</td>
<td>None</td>
<td>If advanced adenoma, repeat in 1 y</td>
</tr>
<tr>
<td>T3, N0, M0 (no high-risk features)</td>
<td>Clinical trial or Observation</td>
<td>If no advanced adenoma, repeat in 3 y, then every 5 y</td>
</tr>
<tr>
<td>T3, N0, M0 at high risk for systemic recurrence</td>
<td>Clinical trial or Observation</td>
<td>Colonoscopy every 3-6 mo or 2 y</td>
</tr>
<tr>
<td>T4, N0, M0</td>
<td>Consider chemotherapy or 5-FU/leucovorin (5-FU/LV)</td>
<td>History and physical every 3-6 mo for 2 y, then every 6 mo for a total of 5 y</td>
</tr>
<tr>
<td>Node-positive disease</td>
<td>see COL.4</td>
<td>Chest/abdominal/pelvic CT annually for up to 5 y for patients at high risk for recurrence</td>
</tr>
</tbody>
</table>

### SURVEILLANCE

- Colonoscopy every 3-6 mo or 2 y for patients at high risk for recurrence
- Colonoscopy every 3-6 mo for 2 y, then every 6 mo for a total of 5 y
- PET-CT scan is not routinely recommended

---

*Note: All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.**

---

**NCCN Guidelines Index**

- Colon Cancer Table of Contents
- Discussion
# Methods

<table>
<thead>
<tr>
<th>COLON CANCER</th>
<th>T1, N0 Stage I</th>
<th>T2, N0 Stage I</th>
<th>T3, N0 Stage IIA (no high risk features)</th>
<th>T3, N0 Stage IIA (high risk)</th>
<th>T4, N0 Stage IIB, C</th>
<th>N1-2-any T Stage III</th>
<th>M1-any T,N Stage IV</th>
<th>Advanced Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polypectomy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resection w/nodes</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Resection liver/lung mets</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Neoadjuvant Therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NeoAdjuv Chemo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NeoAdjuv XRT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NeoAdjuv Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NO ADJUVANT THERAPY</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjuvant Chemotherapy (see preferred chemotherapy regimens sheet)</td>
<td>CONSIDER capecitabine or 5FU/LCV</td>
<td>X or Clinical Trial or Observation</td>
<td>X or Clinical Trial or Observation</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Adjuvant BRM (cetuximab) -- panitumumab is classified as chemotx</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjuvant Radiation Therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Summary

- Compliance with NCCN guidelines varied by stage
- Compliance affected by multiple factors
- Results are impacted by data capture limits
- Future work could use NCCN guidelines as the basis for quality control studies
- Future analysis to include physician reported cases for comparative analysis
Record Linkage

FCDS Annual Meeting
Orlando, FL 2014
Record Linkage

- Refers to:
  - Task of finding records in a data set that refer to the same entity across different data sources.
    - Example: Admissions & Path report @ hospital
    - Example: Cancer Abstract & Death certificate @state registry
  - Joining datasets based on entities that may or may not share a common identifier.
    - Example: @State Registry: SSN
Notable Linkages

• World Trade Center Health Registry Linkage
  o 3 linkages so far since 2008

• Cancer Risk among Firefighters and Emergency Service Rescuers and Officers Exposed to the World Trade Center Disaster
  o 2 linkages to date since 2010

• Cancer in WTC Responders participating in the WTC Medical Monitoring and Treatment Program
  o 1 linkage to date since 2011

• Camp Lejeune Health Survey
  o Assess whether there is an association between exposure to contaminated water at Camp Lejeune and cancer and other specified health conditions
  o 1 linkage to date since 2013
Notable Linkages

• Cancer Epidemiology in Adventists
  o Cohort of 96,000 participants to address broad question of dietary factors that reduce or increase the risk of common cancers.
  o 2 linkages to date since 2011

• Infertility Follow-up study
  o Follow-up on cohort of 12,000+ women to assess cancer risk in relation to causes of infertility and therapeutic regimens used to treat these causes
  o 1 linkage to date since 2011

• Black Women’s Health Study
  o Evaluate causes and preventives of cancers and other serious illnesses in African-American women
  o 5 Linkages to date since 2005

• HIV/AIDS registry match
  o 2 linkages since 2001
Conclusion

- Good demographics vital
  - reliability of match
  - time involved

- Affects quality of match
  - Outside
  - Internal

- Linkages are vital in studying cancer etiology

- $
HIGHLIGHTS FROM THE NAACCR 2014 ANNUAL MEETING

Jill A. MacKinnon, PhD, CTR
Epidemiologist and Project Director, FCDS
NAACCR President
NAACCR 2014

• Ottawa, Ontario, Canada

• Conjoined the meetings of the North American Association of Central Cancer Registries (NAACCR) and the International Association of Cancer Registries (IACR).
NAACCR 2014

• Conference theme, *Capitalizing on Cancer Surveillance Data for Improved Cancer Control*, was shared by both conferences

• This unique educational opportunity provided amazing educational opportunities to learn from local, national, and international experts in cancer surveillance, cancer registry operations, analytical methods, research, and novel ways to use data for cancer control
Meaningful Use
Cancer Reporting

FCDS Annual Meeting
Orlando, Florida
July 24-25th, 2014
Meaningful Use (MU) is a program through the Centers for Medicare and Medicaid Services (CMS) that provides incentives ($) to healthcare providers who use electronic health record (EHR) technology in a specific and ‘meaningful’ way.

Goal is to improve healthcare in the U.S.
How does the CDA get processed?

eMaRC Plus
Physician Reporting Module
User's Guide
Version 1.0
(Based on eMaRC Plus Version 5.1, NAACCR v140)

Centers for Disease Control and Prevention
National Center for Chronic Disease Prevention and Health Promotion
Division of Cancer Prevention and Control
National Program of Cancer Registries
Registry Plus™ Software for Cancer Registries
Data Acquisition Update

FCDS Annual Meeting
July 24 and 25
Data Acquisition Update

- Facility Reporting Counts
- Physician Registration Counts
- Physician Reporting
  - Dermatology Cases Reported
  - Insurance Claims Received
- Facility Reporting
  - Abstracts Received
  - 5 year Review
    - Abstracts received at deadline vs. one year late
- IDEA Batch Receipt for Single Entry - Enhancement
Facility Reporting Counts

- As of July 1, 2014
  - Hospitals 245
  - Radiation Treatment Centers 140
  - Surgery Centers 473

- Net growth since July 2013
  - Hospitals +1
  - Radiation Treatment Centers +4
  - Surgery Centers +44
Scope of Reporting Delay

<table>
<thead>
<tr>
<th>Year</th>
<th>Deadline</th>
<th>1 Year Later</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009 Data</td>
<td>166,303</td>
<td>185,703</td>
</tr>
<tr>
<td>2010 Data</td>
<td>136,610</td>
<td>174,701</td>
</tr>
<tr>
<td>2011 Data</td>
<td>149,368</td>
<td>185,969</td>
</tr>
<tr>
<td>2012 Data</td>
<td>165,991</td>
<td>189,693</td>
</tr>
<tr>
<td>2013 Data</td>
<td>171,179</td>
<td>TBD</td>
</tr>
</tbody>
</table>

• Average 29K cases up to one year late.....
Physician Registration Counts

- Registered as of July 1, 2014
  - HEMA/ONC: 491
  - Hematology: 14
  - Oncologists: 160
  - Urologists: 471
  - Dermatologists: 729
  - Other (MU2): 26
    TOTAL: 1891
- Growth since July 2013: +557
Physician Registration Success

- Dermatology
  - Revised state database identified 891
  - Registered by FCDS 729
  - Registration success rate percentage 82%
- Oncology, Hematology, Urology
  - Revised state database identified 1442
  - Registered by FCDS 1162
  - Registration success rate percentage 80%
Physician Reporting

- Dermatology
  - 2011  5691 cases reported
  - 2012  7647 cases reported
  - 2013  7750 cases reported
  - 2014(as of July 1)  5030 cases reported

Total since inception.....26,118 cases

- 576 of 729 have sent data (79% of registered)
Physician Reporting

- Oncologists 1,125,159 Claims Received
- Urologists 483,570 Claims Received
- HEMA/ONC 4,855,669 Claims Received
- Hematologists 49,690 Claims Received

Total Physician Claims Received 6,514,088
- (as of July 1, 2014)
2014 Cancer Reporting Requirements
2014 FCDS DAM – Summary of Changes
2014 Cancer Reporting Requirements

- NAACCRv14 Required
- FCDS EDITsv14 Metafile

- No New Reportable Cancers
- No New Required Data Items
- Collaborative Stage - Updated to CSv02.05 – Derived TNM/Summary Stage

- 2 Fewer Breast SSFs – HER2 Test – FISH/CISH lab value
  - HER2 FISH/CISH Test Interpretation (+ or –) Still Required
  - When to code SSF14 - HER2: Result of Other or Unknown Test

- AJCC TNM Cancer Staging Items (clinical & pathologic) – Direct Coded TNM
  - Optional for 2014 Cases
  - Basic TNM EDITS will be run
  - FCDS will not include in QC Review
  - CoC-Accredited Facilities Already Code
  - Not Available for FCDS IDEA Single Entry Cases
  - ALL Collaborative Stage Core Items Still Required for 2014 Cases
  - TNM data will be used for Central Registry Planning, Applications Testing, and Training
National Abstracting Coding References

- MPH Rules
- ACOS/CoC FORDS
- SEER*Rx version 2.2.0
- CSv02.05 and Conversion Files
- Instructions for Coding Grade for 2014+
- 2014 Hematopoietic Manual and Database
- ICD-O-3 Updates for United States for 2014
The AJCC TNM Cancer Staging System is based on the clinical, operative, and pathologic assessment of the anatomic extent of disease at the time of initial cancer diagnosis and is used to make appropriate treatment decisions, determine prognosis, and measure end results.

**2014-2015 Transition Years Requirement:** The AJCC TNM Cancer Staging data items may be left blank or may be reported as “Optional” for cancers diagnosed, treated, or else reported to FCDS 1/1/2014-12/31/2015.
- Only CoC-Accredited Facilities can submit “Optional” TNM fields.
- TNM staging requires use of the *AJCC Cancer Staging Manual, 7th edition*.
- TNM Data will not be included in QC Review for 2014-2015.

**2016 Requirement:** AJCC TNM staging requires use of the *AJCC Cancer Staging Manual, 7th edition* for all cancers diagnosed, treated, or otherwise reported to FCDS on or after patient encounters 1/1/2016.
Staging Rules and Definitions of T, N, M (clinical and pathologic) vary across primary sites. You MUST refer to the current *AJCC Cancer Staging Manual* to code AJCC TNM Stage.

- **Clinical Staging** includes any information obtained about the extent of cancer before initiation of definitive treatment (surgery, systemic or radiation therapy, active surveillance, or palliative care) or within four months after the date of diagnosis, whichever is *shorter*, as long as the cancer has not clearly progressed during that time frame.

- **Pathologic Staging** includes any information obtained about the extent of cancer through completion of definitive surgery as part of first course treatment or identified within four months after the date of diagnosis, whichever is *longer*, as long as there is no systemic or radiation therapy initiated or the cancer has not clearly progressed during that time frame.
If you want to abstract, code and send FCDS any 2014 TNM data; You must include all of the TNM Data Items Required.

<table>
<thead>
<tr>
<th>Item Number</th>
<th>Item Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>940</td>
<td>Clinical T</td>
</tr>
<tr>
<td>950</td>
<td>Clinical N</td>
</tr>
<tr>
<td>960</td>
<td>Clinical M</td>
</tr>
<tr>
<td>970</td>
<td>Clinical Stage Group</td>
</tr>
<tr>
<td>980</td>
<td>Clinical Stage (Prefix/Suffix) Descriptor</td>
</tr>
<tr>
<td>990</td>
<td>TNM Clin Staged By</td>
</tr>
<tr>
<td>880</td>
<td>Pathologic T</td>
</tr>
<tr>
<td>890</td>
<td>Pathologic N</td>
</tr>
<tr>
<td>900</td>
<td>Pathologic M</td>
</tr>
<tr>
<td>910</td>
<td>Pathologic Stage Group</td>
</tr>
<tr>
<td>920</td>
<td>Pathologic Stage (Prefix/Suffix) Descriptor</td>
</tr>
<tr>
<td>930</td>
<td>TNM Path Staged By</td>
</tr>
<tr>
<td>1060</td>
<td>TNM Edition Number</td>
</tr>
</tbody>
</table>

DO NOT ENTER ANY OF THE COLLABORATIVE STAGE DERIVED TNM VALUES IN THESE FIELDS – THESE ARE FOR DIRECT-CODED TNM ONLY
Florida Cancer Data System
2014 Implementation Guideline
NAACCR Version 14
Record Layout and Data Standard Recommendations

July 1, 2014 (original)
(Date of Last Update - 4/10/2014)

To Contact Us:
University of Miami Miller School of Medicine
Fox Building - Room 410
1550 NW 10th Ave
Miami, Florida 33136
Phone: (305) 243-4600
Fax: (305) 243-4871

Data Acquisition Manual 2014
2014 FCDS DAM - Summary of Changes

NEW OR ADDED SECTION OR DATA ITEMS

SECTION A - Abstracting and Coding Instructions
- AACR TMM Cancer Staging System Section - TMM is "optional" for cancer-registered facilities only in 2014
  - Clinical T, N, M and AACR Clinical Stage Group Items
  - Clinical TMM - Staged By
  - Pathologic TMM and AACR Pathologic Stage Group Items
  - Pathologic TMM - Staged By
  - Peer Description (clinical and pathologic)
  - TMM Edition Number

APPENDICES
- Appendix A - Instructions for coding grades for 2014 (from the AACR/NCI/NBCR technical vs.og)
- Appendix B - ICD-10-CM Casefinding List for Reportable Tumors (must be used 10/1/2015 forward)

UPDATED OR CLARIFICATION OF SECTION OR DATA ITEMS

SECTION A - General Instructions
- New, reportable malignancies: Clear cell renal cell, renal cell cancer, and renal cell cancer with metastasis
- Section B - Casefinding - Implementation of ICD-10-CM/PCS with Casefinding Instructions
- Section C - Casefinding - Pathology Casefinding is required
- Section D - ICD-10-CM Casefinding List for Reportable Tumors
- Section E - ICD-10-CM Abstractor Code Policy and Coding Requirements
- Section F - OCC ROIS and the FCDS 6-month Case Abstracting Requirement (Timeliness)
- Section G - Required/Recommended Desktop References
- Section H - Data Transmission and Quarterly Reporting to FCDS
- Section I - Data Acceptance Policy - FCDS EDITS
- Section J - FCDS Data Quality Indicator Report (DQR)
- Section K - Cancer Registry Awards - Audit Award for Excellence in Cancer Registry Abstracting
- Section L - Sample 2014 FCDS Reporting Calendar
- Section M - January 2014 FCDS Abstract (do not send to FCDS)

SECTION B - Abstracting and Coding Instructions
- Several data item definitions were updated/certified:
  - Reporting Facility
  - Accrual Number - Hospital
  - Sequence Number - Hospital
  - Data Complete - Data Abstracted
  - Social Security Number - No Partial Records Allowed
  - Birthplace State and Birthplace Country - Clarification
  - Address at DX State and Address at DX Country - Clarification
  - Address current state and address current country - Clarification
  - Tumor usual occupation and usual work industry
  - Primary Site
    - Use of CT, PET Primary Site Discontinued
    - Head and Neck Cancer with No Primary Site Identified
    - Metastatic carcinomas of specific type with no primary site identified
    - Grade/Differentiation/Immunophenotype
      - entire section rewritten for "Grade Coding Instructions for 2014"
    - Lymph Vascular Invasion - Clarified
    - Treatment - Clarification for coding Aspirin, Poliomyelitis, and Radiation Therapy
COLLABORATIVE STAGE DATA COLLECTION SYSTEM (CSv)

Collaborative Staging (CS) is to be used for all cases regardless of date of diagnosis until 12/31/2015. For Collaborative Staging, registers code discrete pieces of information once and the CS composite algorithm derives the values for the 6th and 7th editions of the AJCC Cancer Staging Manual, 7th and 8th Editions, and descriptors, as well as Summary Stage 1977 and Summary Stage 2000. The training rule for CS coding is designed to make use of the most complete information possible to yield the “best case” information for the tumor at the time of diagnosis—use all information gathered through completion of surgery(ies) in first course of treatment or all information available within four months of the date of diagnosis to determine disease stage. Disease stage is defined as further disease extension or distant metastases known to have developed after the diagnosis was established. Information about treatment extension, lymph node involvement, or distant metastases obtained after disease progression is documented should be excluded from the CS coding.

FCDS will collect all the required CS data in accordance with the latest version of CS, current version 02.05, and necessary to derive AJCC TNM Staging 6th and 7th edition and SEER Summary Stage 2000. This includes CS data collection for all schemes and clinical descriptions (CSv) for applicable cases consistent with CDC NPCR and the Florida Department of Health requirements.

The following CS data items need to be coded for all schemes. Items with an asterisk (*) have site-specific variations for some codes:

- CS Tumor Site (NACCR Item #2800)
- CS Extent (NACCR Item #2810)
- CS Tumor Size (NACCR Item #2820)
- CS Lymph Node (NACCR Item #2840)
- CS Ki-67 Lymph Node Status (NACCR Item #2850)
- CS Metastatic Lymph Node (NACCR Item #2860)
- CS Metastatic Bony Status (NACCR Item #2870)

CS Site-Specific Factors 1–22 are required for collection based on the site-specific schema selection. See Appendix B for a complete list of site-specific CSv requirements for 2015 to go to http://www.cancerdata.org to see all site-specific schemas and the required Site-Specific Factors. This spreadsheet is subject to change based on AJCC CSv revisions.

Coding CS Data Items:
The complete instructions and site-specific definitions are available in the current version of Collaborative Stage Data Collection System [http://www.cancerdata.org/ctds/]

CSv02.05 Required

2014 Optional TNM
LYMPH-VASCULAR INVATION

LYMPH-VASCULAR INVATION or LVI indicates the presence or absence of tumor cells in small lymphatic channels (not lymph nodes) or small blood vessels within the primary tumor or in the surrounding tissues of the primary site as noted microscopically by the pathologist. When a neoplasm shows the presence of lymph-vascular invasion, tumor cells have broken free of the primary tumor and now have the ability to float throughout the body. Therefore, lymph-vascular invasion may be used an indicator of prognosis.

Benign, borderline and in-situ neoplasms cannot have lymphatic or vascular invasion by definition. When any invasion is present, the neoplasm is classified as malignant with behavior = 3.

Lymphoid and myeloid neoplasms (neoplasms that originate in the lymphatic system, bone marrow, or in circulating blood) cannot have lymphatic or vascular invasion. Only solid tumors may have LVI.

Lymphatic invasion is not the same as involvement of regional lymph nodes.

Lymph-vascular invasion does not include perineural invasion.

Coding Instructions
1. The primary source of this information is the pathology report or a physician’s statement.
2. Use code 0 when behavior = 0, 1, or 2 (ALL benign, borderline, and in-situ neoplasms).
3. Use code 0 when the pathology report states that no lymph-vascular invasion was identified.
4. Use code 1 when lymph-vascular is identified anywhere in a primary tumor specimen.
5. Use code 8 when histology = 9590-9992 (ALL lymphoid and myeloid neoplasms).
6. Use code 9 if the pathology report indicates that the presence of lymph-vascular invasion could not be determined or when no information is available in the pathology report or medical record.
7. Use code 9 when no tissue from the primary site was examined (invasive solid tumors only).

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Behavior = 0, 1, or 2 (benign, borderline or in-situ neoplasm)</td>
</tr>
<tr>
<td>0</td>
<td>Lymph-vascular invasion not present (absent)/not identified</td>
</tr>
<tr>
<td>1</td>
<td>LVI Present/Identified</td>
</tr>
<tr>
<td>8</td>
<td>Histology = 9590-9992 (lymphoid or myeloid neoplasm)</td>
</tr>
<tr>
<td>9</td>
<td>LVI Unknown, Indeterminate, Not Stated, or no tissue from primary site was examined</td>
</tr>
</tbody>
</table>
Participation in RQRS is Voluntary – Commendation-Only Standard 5.2 – Replaces CoC 6-month timing requirement

FCDS 6-MONTH REPORTING REQUIREMENT - NO CHANGE

COMPLETE Case Reports (Abstracts) Are Still Required to be sent to FCDS on or before Annual Deadline of June 30

You may have to report a few cases to FCDS that are still flagged as “incomplete” at the time of FCDS Annual June 30th Reporting Deadline – this may occur when the case must be reported for deadline and the abstract includes all information available at the time of deadline. But, the case must still pass FCDS EDITS.
2014-2015 Education & Training Plan
FCDS Webcast Series and VoIP Audio
## 2014-2015 FCDS Webcast Schedule

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Presentation Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>8/21/2014</td>
<td>1:00pm – 3:00pm</td>
<td>2014 Reporting Requirements: FCDS Annual Meeting Highlights</td>
</tr>
<tr>
<td>9/18/2014</td>
<td>1:00pm – 3:00pm</td>
<td>GYN Neoplasms: Background, Anatomy, Risk Factors, Signs and Symptoms, MPH Rules, Staging (CSv02.05, SSFs, TNM, SS) and TX</td>
</tr>
<tr>
<td>10/16/2014</td>
<td>1:00pm – 3:00pm</td>
<td>Neuroendocrine Tumors (NET) and GI Stromal Tumors (GIST): Background, Anatomy, Risk Factors, Signs and Symptoms, MPH Rules, Staging (CSv02.05, SSFs, TNM, SS) and TX</td>
</tr>
<tr>
<td>11/20/2014</td>
<td>1:00pm – 3:00pm</td>
<td>Reportable Skin Cancers: Background, Anatomy, Risk Factors, Signs and Symptoms, MPH Rules, Staging (CSv02.05, SSFs, TNM, SS) and TX</td>
</tr>
<tr>
<td>1/15/2015</td>
<td>1:00pm – 3:00pm</td>
<td>Genitourinary Neoplasms (Kidney, Bladder, Prostate, Penis): Background, Anatomy, Risk Factors, Signs and Symptoms, MPH Rules, Staging (CSv02.05, SSFs, TNM, SS) and TX</td>
</tr>
<tr>
<td>2/19/2015</td>
<td>1:00pm – 3:00pm</td>
<td>Lower GI Tract Neoplasms: Background, Anatomy, Risk Factors, Signs and Symptoms, MPH Rules, Staging (CSv02.05, SSFs, TNM, SS) and TX</td>
</tr>
</tbody>
</table>

**FCDS Educational Webcast Series Re-Starts in August 2015 Following the FCDS Annual Meeting**
## 2014-2015 NAACCR Webinar Schedule

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Presentation Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/2/2014</td>
<td>9:00am - 12:00pm</td>
<td>Directly-Coded Stage: Using the AJCC Cancer Staging Manual and Summary Stage 2000</td>
</tr>
<tr>
<td>11/6/2014</td>
<td>9:00am - 12:00pm</td>
<td>Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms</td>
</tr>
<tr>
<td>12/4/2014</td>
<td>9:00am - 12:00pm</td>
<td>Using the Multiple Primary and Histology (MP/H) Coding Rules</td>
</tr>
<tr>
<td>1/8/2015</td>
<td>9:00am - 12:00pm</td>
<td>Collecting Cancer Data: Testis</td>
</tr>
<tr>
<td>2/5/2015</td>
<td>9:00am - 12:00pm</td>
<td>Collecting Cancer Data: Uterus</td>
</tr>
<tr>
<td>3/5/2015</td>
<td>9:00am - 12:00pm</td>
<td>Abstracting and Coding Boot Camp: Cancer Case Scenarios</td>
</tr>
<tr>
<td>4/2/2015</td>
<td>9:00am - 12:00pm</td>
<td>Collecting Cancer Data: Stomach &amp; Esophagus</td>
</tr>
<tr>
<td>5/7/2015</td>
<td>9:00am - 12:00pm</td>
<td>Collecting Cancer Data: Larynx and Thyroid</td>
</tr>
<tr>
<td>6/4/2015</td>
<td>9:00am - 12:00pm</td>
<td>Collecting Cancer Data: Pancreas</td>
</tr>
<tr>
<td>7/9/2015</td>
<td>9:00am - 12:00pm</td>
<td>Survivorship Care Plans</td>
</tr>
<tr>
<td>8/6/2015</td>
<td>9:00am - 12:00pm</td>
<td>Collecting Cancer Data: Central Nervous System</td>
</tr>
<tr>
<td>9/3/2015</td>
<td>9:00am - 12:00pm</td>
<td>Coding Pitfalls</td>
</tr>
</tbody>
</table>
NAACCR Webinar Host Sites

- 7 FCDS-Hosted Sites
- Geographically Dispersed
- Registration Requested
- Encourage Attendance
- Recordings Available
- 3 CEUs per Webinar
- No Cost to Registrar/Host

<table>
<thead>
<tr>
<th>Host Site</th>
<th>City</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baptist Regional Cancer Center</td>
<td>Jacksonville</td>
</tr>
<tr>
<td>Boca Raton Community Hospital</td>
<td>Boca Raton</td>
</tr>
<tr>
<td>Gulf Coast Medical Center</td>
<td>Panama City</td>
</tr>
<tr>
<td>H. Lee Moffitt Cancer Center</td>
<td>Tampa</td>
</tr>
<tr>
<td>UF Health Cancer Center Orlando Health</td>
<td>Orlando</td>
</tr>
<tr>
<td>Shands University of Florida</td>
<td>Gainesville</td>
</tr>
<tr>
<td>FCDS</td>
<td>Miami</td>
</tr>
</tbody>
</table>
NAACCR CTR Prep Webinars

- The NAACCR CTR Exam Preparation & Review Webinar Series offers online instruction with experienced faculty. The course includes eight 2-hour sessions, sample CTR Exam and a follow-up post exam session. All sessions are recorded and available for playback 24/7 via Drop Box.

- Individual Subscription for the Series is $400 – includes “live” sessions

- FCDS picks up the $400 fee for any Florida candidate CTR
  - This is NOT a Beginner Abstracting Course
  - Candidate CTRs must be planning to write the CTR Exam
  - Florida candidate CTRs must view recordings as part of agreement
  - This allows you to watch each session whenever time allows
  - All Course Materials including Sample CTR Exam are included
  - Contact and Feedback from Course Instructors is included
  - Next CTR Exam Prep and Review Series begins in mid-August
“Staging of Cancer”

- Transition Training from CS to Direct-Coded TNM and SS2000
- Teaching All 3 Staging Approaches/Systems in Webcasts
- Reinforce Biomarker and Prognostic Indicator Tests
- Identify Additional Available Resources – Concept (How To) Training
- Identify Additional Available Resources – Practice Cases
- Tap Into National Training Efforts
- QC of TNM and Summary Stage will begin with 2016 dx/admit
- FCDS Text Requirements – Never More Critical Than Now
<table>
<thead>
<tr>
<th>Date</th>
<th>Duration</th>
<th>Title</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>August 21, 2009</td>
<td>60 min</td>
<td>Debunking Urban Legends in Staging</td>
<td>This presentation is intended to provide physicians and cancer registrars with highlights of the AJCC staging rules, especially the changes that have taken place in the 7th Edition, which become effective with cases diagnosed January 1, 2010.</td>
</tr>
<tr>
<td>January 6, 2010</td>
<td>60 min</td>
<td>AJCC Seventh Edition Staging Series: Shaping the Future: An Overview Presentation on the 7th Edition AJCC Cancer Staging Manual</td>
<td>The purpose of this presentation is to highlight the major changes in the 7th edition and review the new and emerging prognostic factors related to cancer staging.</td>
</tr>
<tr>
<td>February 24, 2010</td>
<td>60 min</td>
<td>AJCC Seventh Edition Staging Series: The Staging of Colorectal Cancer: What’s New in the Seventh Edition of the AJCC Cancer Staging Manual</td>
<td>The purpose of this presentation is to review the major changes in the 7th edition for colorectal cancer staging and to highlight new and emerging prognostic factors related to colorectal cancer staging.</td>
</tr>
<tr>
<td>March 15, 2010</td>
<td>60 min</td>
<td>AJCC Seventh Edition Staging Series: Staging Head and Neck Cancers - Transitioning to the Seventh Edition of the AJCC Cancer Staging Manual</td>
<td>This presentation summarizes the criteria used in the new staging schema for head and neck tumors, and outlines the rationales behind the changes.</td>
</tr>
<tr>
<td>March 29, 2010</td>
<td>60 min</td>
<td>AJCC Seventh Edition Staging Series: The New Staging System for Lung Cancer - A Clear View of Prognostics</td>
<td>The purpose of this presentation is to review the major changes in the 7th Edition for Lung Cancer Staging and to highlight new and emerging prognostic factors related to lung cancer staging.</td>
</tr>
<tr>
<td>April 13, 2010</td>
<td>60 min</td>
<td>AJCC Seventh Edition Staging Series: The AJCC Cancer Staging Manual, 7th Ed Staging for Esophagus and Stomach: A Simplified Road Map for Tumor Location</td>
<td>The purpose of this presentation is to review the major changes in the Seventh Edition for Esophagus and Stomach Cancer Staging and to highlight new and emerging prognostic factors related to the staging.</td>
</tr>
<tr>
<td>August 18, 2010</td>
<td>60 min</td>
<td>AJCC and FIGO: Unified Staging of Gynecologic Disease Sites</td>
<td>The purpose of this presentation is to highlight the major changes for all of the Gynecological Sites.</td>
</tr>
<tr>
<td>September 16, 2010</td>
<td>60 min</td>
<td>What’s New in GI Staging: Gastrointestinal Stromal Tumors, Neuroendocrine Tumors of the GI Tract, and Endocrine Tumors of the Pancreas</td>
<td>This presentation is intended to highlight the major changes for Neuroendocrine, Gastrointestinal Stromal and Endocrine Pancreatic Tumors.</td>
</tr>
<tr>
<td>November 3, 2010</td>
<td>60 min</td>
<td>TNM Staging for Kidney and Adrenal Gland</td>
<td>The purpose of this presentation is to highlight the major changes for Kidney and Adrenal Gland including Ipsilateral adrenal involvement reclassification and the simplification of nodal involvement.</td>
</tr>
<tr>
<td>November 10, 2010</td>
<td>60 min</td>
<td>New Classifications of Appendiceal Tumors and Understanding the Connection Between Appendix and Ovary: A Pathologist View</td>
<td>The purpose of this presentation is to highlight the major changes for Appendix and Ovary and demonstrate the important connection the sites share.</td>
</tr>
<tr>
<td>December 15, 2010</td>
<td>60 min</td>
<td>Melanoma and Merkel Cell Carcinoma Staging</td>
<td>The purpose of this presentation is to highlight the major changes for Melanoma and Merkel Cell Carcinoma.</td>
</tr>
<tr>
<td>May 8, 2012</td>
<td>40 min</td>
<td>AJCC and UICC: Tumor Deposits in Colorectal Cancer</td>
<td>The purpose of this presentation is to highlight the criteria and provide guidance on the new Nc category. The presentation answers frequently asked questions on tumor deposits with a united voice from the AJCC and UICC.</td>
</tr>
</tbody>
</table>
# AJCC TNM Stage - Available Resources

## Articles and Manuscripts on AJCC TNM Staging System


**New N Staging System of Penile Cancer Provides a Better Reflection of Prognosis, Yao Zhu, Ding-Wei Ye, Xu-Dong Yao, Shi-Lin Zhang, Bo Dai and Hai-Liang Zhang**

**TNM: Our Language of Cancer, Frederick L. Greene, MD, FACS**

**The Staging of Cancer: A Retrospective and Prospective Appraisal, Frederick L. Greene, MD, et al.**

**Comparison of Registrar Collaborative Staging and Physician AJCC Staging Using Date Submitted to the National Cancer Data Base, Phillips, JL, Gress, DM, Journal of Registry Management Spring 2008.**

**The "y" Symbol: an Important Classification Tool for Neoadjuvant Cancer Treatment, Brierley, JD, Greene, FL, Sobin, LH, Wittekind, C. Cancer 2006; 106:2526-7.**

**On the Use and Abuse of X in the TNM Classification, Frederick L. Greene, MD, FACS Cancer 2005; 103:647-649.**

**The AJCC the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM, Stephen B. Edge, MD and Carolyn C. Compton, MD PhD, Annals of Surgical Oncology 2010**

**2010 TNM Staging System for Cutaneous Melanoma and Beyond, Jeffrey E. Gershenwald, MD, Seng-jaw Soong, PhD, Charles M. Balch, MD, Annals of Surgical Oncology 2010**

**7th Edition AJCC Cancer Staging Manual Stomach, Mary Kay Washington, Md PhD, Aannals of Surgical Oncology 2010**

**Creating and Providing Predictions of Melanoma Outcome, Kenneth K. Tanabe, MD, Sebastian Jara, BSc, and James Michaelson, PhD. Annals of Surgical Oncology 2010**

Resources for Practice Cases

- AJCC You Tube “Staging Moments” – free
- SEER*Educate Website – free
  - More than 500 Cases – 50 cancer sites
- FCDS Webcast Series – free
  - Practice Cases will be included for most webcasts
  - Will reduce some of the content provided
  - Go To Meeting Poll for Interactive Q&A
- NCRA Workbook for the Staging of Cancer - $75
  - Overview of Basic Principles of AJCC TNM Staging System plus Practice Cases
  - 8 Sites - Head & Neck, Colon, Breast, Ovary, Prostate, Testis, Bladder, Lymphoma
- April Fritz “The Cancer Registry CASEbook(s)” - $75 each
  - Volume I - Introduction and 5 Sites - Colon, Breast, Lung, Prostate, Bladder
  - Volume II - Challenging Sites - Head & Neck, Female Genital, CNS, Lymphoma
FCDS Webcast Series with VoIP Audio
Using GoToMeeting to Full Potential

- Delivered to Your Desktop with Live Interactive Meetings

- No More Toll Free Number to Call In if you use VoIP
  - VoIP is easy to use and you are probably already set up to use it
  - Individuals may opt to pay long distance charges instead of VoIP

- Goal is to allow more time for Q&A using polls/surveys

- Also to allow time for Brief Discussion of Practice Cases

- All Webcasts will continue to be available in recorded format
Audio Options

- Use USB Headset and Voice-Over Internet Protocol (VoIP) – free
- Use internal microphone and internal laptop speakers – free
- Use external webcam with built-in microphone and speakers – free
- Use Provided Phone Line – may incur long distance charges

- CAUTION – You Cannot Use Both VoIP and Telephone
- CAUTION – Avoid Setup Problems that cause ECHO during webcast
  - VoIP setup – audio from speakers reaches the microphone
  - Phone setup – audio from a computer feeds into the telephone

- The person causing the echo does not hear the echo!!

- Use headset whenever possible to avoid echo
- Use headset whenever possible to minimize disruption to others
- If you use telephone for audio – be sure to enter the Audio PIN when asked upon entry into the webcast – a notice will appear with the PIN #
Audio Options and Audio Setup Instructions

Listed in order from best quality to poor quality:

1. USB headset connected to your computer - Best
2. Headphones and USB microphone connected to your computer
3. Analog headset connected to your computer - Good
4. Headphones and analog microphone connected to your computer
5. External speakers and USB microphone - Fair
6. External speakers and analog microphone
7. Laptop built-in microphone and speakers - Poor
8. External speakers and USB Webcam microphone
Using a Headset

- A quality headset separates your computer’s microphone from the speakers on your computer and helps you focus.
- Allows you to listen and talk – speaker and microphone
- Eliminates your neighbors from having to listen, too.
- Reduces Background Noise and Eliminates Echo Potential
- Speak Clearly – there may be a few seconds wait time to hear
- Use Chat Window to Avoid Interrupting Speaker
- Know How to Use Your Mute Button
- Types of Headsets
  - Wraparound headset with built-in microphone
  - Webcam with built-in microphone
  - Ear “buds” – listen only
- Price Range - $10-$500
Enhancing Central Cancer Registry Treatment Data using Physician Medical Claims: A Florida Pilot Project

FCDS Annual Meeting
July 24-25, 2014
Caribe Royale Resort
Orlando, Florida
Introduction

- Data collected by central cancer registries is utilized for patient outcomes research
- Requires complete detailed treatment data
- Capturing information from physician offices can improve cancer surveillance without increased burden on physicians
Medical claims from hospitals and Medicare have been used by central registries for case ascertainment and data enhancement.

Use of claims from physician offices offers more complete dataset.

Enables longitudinal tracking.

Updates patient information with each encounter.
Medical Claims Crosswalks

- To efficiently gather claims information
  - Need to automate and translate data from medical claims forms
  - Convert data into established standard coding layouts for national cancer reporting

- Crosswalk/derive treatment/procedure codes to cancer registry codes
  - ICD-9-CM – International Classification of Disease, 9th revision
  - HCPC – Healthcare Common Procedure Coding System

  - Anti-neoplastic agents, RT, Hormones
  - Ancillary therapies to enhance chemo tolerance
## APPENDIX C

CPT / HCPCS Procedure Codes List

SAMPLE ONLY - NOT a Complete List of Codes

(Procedures Indicate Patient Encounter was for the Diagnosis and/or Treatment of Neoplasm)

Note: Any CPT/HCPCS code that indicates a patient encounter related to the diagnosis or treatment of any neoplasm that meets the Case Eligibility Criteria described in Section I Part A should be included. A complete CPT/HCPCS code list would include diagnostic and surgical procedure(s) used to establish a diagnosis or to surgically remove primary or metastatic cancer; administration or prescribing of any chemotherapeutic agent(s), immunotherapy agent(s), or biological response modifier(s), administration of radiation therapy of any type (beam radiation, radioactive implants, radioisotopes, brachytherapy, IMRT, gamma knife), blood, bone marrow or stem cell transplant procedure(s), endocrine gland resection for treatment of prostate, breast, or other cancer, and other cancer-directed therapy(s).

<table>
<thead>
<tr>
<th>Coding System</th>
<th>Code</th>
<th>Brief Description</th>
<th>Detailed Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>96412</td>
<td>CHEMOTHERAPY, INFUSION METHOD.</td>
<td>CHEMOTHERAPY ADMINISTRATION, INTRAVENOUS INFUSION TECHNIQUE, ONE TO 8 HOURS, EACH ADDITIONAL HOUR (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)</td>
</tr>
<tr>
<td>CPT</td>
<td>96414</td>
<td>PROLONGED INFUSION MORE THAN 8 HRS</td>
<td>CHEMOTHERAPY ADMINISTRATION, INTRAVENOUS INFUSION TECHNIQUE, INITIATION OF PROLONGED INFUSION (MORE THAN 8 HOURS), REQUIRING THE USE OF A PORTABLE OR IMPLANTABLE PUMP</td>
</tr>
<tr>
<td>CPT</td>
<td>96420</td>
<td>CHEMOTHERAPY, PUSH TECHNIQUE.</td>
<td>CHEMOTHERAPY ADMINISTRATION, INTRA-ARTERIAL; PUSH TECHNIQUE</td>
</tr>
<tr>
<td>CPT</td>
<td>96422</td>
<td>CHEMOTHERAPY, INFUSION METHOD...</td>
<td>CHEMOTHERAPY ADMINISTRATION, INTRA-ARTERIAL; INFUSION TECHNIQUE, UP TO ONE HOUR</td>
</tr>
<tr>
<td>CPT</td>
<td>96423</td>
<td>CHEMOTHERAPY, INFUSION METHOD....</td>
<td>CHEMOTHERAPY ADMINISTRATION, INTRA-ARTERIAL INFUSION TECHNIQUE, ONE TO 8 HOURS, EACH ADDITIONAL HOUR (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)</td>
</tr>
<tr>
<td>CPT</td>
<td>96440</td>
<td>CHEMO ADM INTO PLEURAL CAVITY/THORACENTESIS</td>
<td>CHEMOTHERAPY ADMINISTRATION INTO PLEURAL CAVITY, REQUIRING AND INCLUDING THORACENTESIS</td>
</tr>
<tr>
<td>CPT</td>
<td>96450</td>
<td>CHEMOTHERAPY, INTO CNS</td>
<td>CHEMOTHERAPY ADMINISTRATION, INTO CNS (e.g., INTRATHECAL), REQUIRING AND INCLUDING SPINAL PUNCTURE</td>
</tr>
<tr>
<td>CPT</td>
<td>96520</td>
<td>PUMP REFILLING, MAINTENANCE</td>
<td>REFILLING AND MAINTENANCE OF PORTABLE PUMP</td>
</tr>
<tr>
<td>HCPCS</td>
<td>J1830</td>
<td>Interferon beta-1b / .25 MG</td>
<td>INJECTION INTERFERON BETA-1B, 0.25 MG</td>
</tr>
<tr>
<td>HCPCS</td>
<td>J8520</td>
<td>Capcitabine, oral, 150 mg</td>
<td>CAPECITABINE, ORAL, 150 MG</td>
</tr>
<tr>
<td>HCPCS</td>
<td>J8521</td>
<td>Capcitabine, oral, 500 mg</td>
<td>CAPECITABINE, ORAL, 500 MG</td>
</tr>
<tr>
<td>HCPCS</td>
<td>J8530</td>
<td>Cyclophosphamide oral 25 mg</td>
<td>CYCLOPHOSPHAMIDE; ORAL, 25 MG</td>
</tr>
<tr>
<td>HCPCS</td>
<td>J8560</td>
<td>Etoposide oral 50 MG</td>
<td>ETOPOSIDE; ORAL, 50 MG</td>
</tr>
</tbody>
</table>
Claims Processing

- FCDS Transmission (SFTP) Patient-Tumor-Matching
- Claim Database
- Treatment Mapping Table (claims codes-Fords-NAACCR)
- PACS Processing Abstracts from Claims

NAACCR Consolidated Patient-Tumor Abstract

- Claim-Only Abstract (case finding)
- Links with hospital abstract (case augmentation)
- Links with Path Report (histology/laterality)
Objective: To validate the processing of claims and to evaluate enhancement to chemo treatment information

Background: Florida is one of ten states funded for the Comparative Effectiveness Research project. Part of funding for this project aimed at expansion of physician cancer reporting

Claims captured 41% with chemotherapy, compared to 28% in the registry dataset.

45% of cases with chemotherapy captured in the gold standard CER data.
FCDS IDEA Follow Up System

Gary M. Levin, CTR, BA
FCDS Annual Meeting
July 24th, 2014
Benefits To Your Registry

Possible Data Delivery Methodology

- Allow Upload Of List of Cases Needing Follow Up
  - Will Define File Layout
  - Will Define Maximum Number Of Cases Per Upload
  - Will Have Access To Facilities Assigned Via IDEA

- Return Information For Each Requested Case
  - Information Will Include
    - Facility/Accession/Sequence
    - First Course Treatment Information + TBD
- Return Data In Tab Delimited or Excel File
Facility Follow Up System
Pilot Testers Recognition

• Phase I Pilot Testers (Started 5/14/2014)
  • Sara J. Holton, CTR – Mayo Clinic
  • Kelly King, CTR – Cleveland Clinic

• Phase II Pilot Testers (Started 6/26/2014)
  • Merci Mena-Allauca, CTR, RHIT – Baptist Health System
  • Ana L. Ruiz, CTR – Mount Sinai Medical Center
Facility Follow Up System
Pilot Testers Recognition

• Tested module to ensure error free

• Analyzed Results
  • Checking Date of Last Contact
  • Comparing Treatment Information
  • Impact on follow back rates

• Shared findings and issues

• Recommended improvements
Facility Follow Up System
When Will This Be Available You Ask?

Depending On Time And Budgetary Resources By The End Of 2013

During 4th Quarter 2014 (Hopefully by August)
2014 FCDS Data Validation Audit
Diagnosis Year 2012 Cases

BACKGROUND
AUDIT METHODOLOGY
AUDITOR VALIDATION EXAMPLE
FACILITY RECONCILIATION EXAMPLE

FCDS ANNUAL CONFERENCE
ORLANDO, FL
7/24/2014

STEVEN PEACE, CTR
Data Validation with E-Path Verification

- Audits may include manual/visual review of one or more source documents, data linkages of one or more electronic files from reporting facilities with the central cancer registry database with a cross-walk and/or comparison of output results.

- This audit has 2 components:
  - **First:** a focused review of analytic breast and colon cancer cases diagnosed/treated at the facility with validation (recoding) of data from text only;
  - **Second:** a focused review of e-pathology report(s) from any e-path report source matching hospital registry abstracts with recode of data from pathology report(s).

- Facilities are required to reconcile BOTH data sets for a best code.
- Additional documentation will be required if not available.
The visual editing validation and recoding of key data component of this audit is modeled after the NPCR Visual Editing Audit conducted early in 2013 for 2010 diagnoses and consolidation.

This method utilizes FCDS standard visual editing/QC Review procedures used to convey review findings targeted to specific cancers (breast and colon) that were also part of the CER Project.

NOTE: Text Documentation of specific data items has been both a state and national cancer reporting requirement for nearly two decades with requirements and expectations reinforced via QC Review or personal contact with registrars on a routine basis.
## Timeline

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol Development</td>
<td>Protocol Development</td>
<td>Final Protocol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Software Development</td>
<td>Software Development</td>
<td>Software Development</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Identify Audit Team</td>
<td>Train Audit Team</td>
<td>Follow-Up Audit Team</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Audit</td>
<td>Audit</td>
<td>Audit</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reconciliation</td>
<td>Reconciliation</td>
<td>Reconciliation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Final Review</td>
<td>Final Review</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Update FCDS Record</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Preliminary Audit Report</td>
<td>Final Audit Report</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
2013 Jean Byers Award

FCDS Annual Meeting July 24 & 25
2013 Jean Byers Award

• 2013 award for 2011 data awarded in 2014!
• Criteria for the award:
  • All deadlines met with respect to the 2011 cancer case admissions
    • b. Consolidated Follow Back Deadline – October 15, 2013
    • c. No more than 5% (or 35 cases, whichever number is greater) of the 2011 cancer case admissions reported to FCDS within 2 months (60 days) following the June 30, 2012 deadline.
    • d. No more than 10% of the 2011 cancer case admissions reported to FCDS within 12 months following the June 30, 2012 reporting deadline.
FCDS Annual Meeting of the Future

Jill A. MacKinnon, PhD, CTR
Epidemiologist and Project Director
2013 FCDS QC Activities Summary

FCDS ANNUAL CONFERENCE
ORLANDO, FL
7/25/2014

STEVEN PEACE, CTR
# Submission Summary & QC Review Sample

<table>
<thead>
<tr>
<th>Description</th>
<th># Cases</th>
<th>% of Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cases Submitted to FCDS 1/1/2013-12/31/2013 – All Sources</td>
<td>197,208</td>
<td>100%</td>
</tr>
<tr>
<td>Total Cases – NO CHANGE – Pass ALL Edits – No Visual Review by FC or QC</td>
<td>187,163</td>
<td>95.0%</td>
</tr>
<tr>
<td>Total Cases – FC Visual Review <em>(FC Review to assess case for possible FORCE)</em></td>
<td>10,045</td>
<td>5.0%</td>
</tr>
<tr>
<td>• FORCED <em>(EDIT Override Confirmed and FORCE was set - NOT an error)</em></td>
<td>4,003</td>
<td>2.0%</td>
</tr>
<tr>
<td>• CORRECTED <em>(1 or more corrections made based on text – NOT a FORCE)</em></td>
<td>4,519</td>
<td>2.3%</td>
</tr>
<tr>
<td>• DELETED <em>(duplicate case, not a reportable neoplasm, not a new primary)</em></td>
<td>1,523</td>
<td>0.7%</td>
</tr>
<tr>
<td>Total Cases – Every 25th Case QC Review Sample/Visual Editing</td>
<td>6,067</td>
<td>3.2%</td>
</tr>
<tr>
<td>• Sample includes 4% of analytic hospital, radiation, surgery center cases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Sample includes ALL male breast and ALL pediatric cases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Sample does not include dermatology or other physician office cases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Cases Visually Edited by FCDS in 2013 <em>(combined FC and/or QC Review)</em></td>
<td>16,112</td>
<td>8.2%</td>
</tr>
</tbody>
</table>
## QC Review Sample / Visual Editing - Summary

<table>
<thead>
<tr>
<th>Description</th>
<th># Cases</th>
<th>% of Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cases – Every 25\textsuperscript{th} Case QC Review Sample/Visual Editing</td>
<td>6,067</td>
<td>3.2% of Analytic Cases</td>
</tr>
<tr>
<td>Total Cases – NO CHANGE on QC Review</td>
<td>3,486</td>
<td>57.5% of QC Sample</td>
</tr>
<tr>
<td>Total Cases Sent to Facility with Correction or Inquiry</td>
<td>2,581</td>
<td>42.5% of QC Sample</td>
</tr>
</tbody>
</table>

### Total Cases Sent to Facility with Correction or Inquiry

- NO CHANGE after Follow-Back to Facility: 374 (14.5%)
- FORCED (EDIT Override Confirmed - NOT an error): 46 (1.8%)
- CORRECTED (1 or more corrections made – NOT a FORCE): 2,125 (82.3%)
- DELETED (duplicate case, not a reportable neoplasm, not a new primary): 36 (1.4%)
A new or enhanced QC Completion Analysis Report would benefit FCDS and registrars in the field if we would provide a QC Review Summary Report by Facility and by Abstractor Code that would include the following items or grouped items.

Three Summary Reports
- Summary by Facility
- FCDS State Summary
- Summary by Abstractor Code

Summary Items - General
- # Cases Reviewed with No Change
- # Cases Reviewed with Correction with Breakdown by Type of Correction
- # Cases Reviewed Requiring Force
- # Cases Reviewed and Deleted
- Total QC Review Cases

Summary Items from Correct Cases - Aggregated into 6 Major Groups for all Three Summary Reports

- Patient Demographic
- Tumor Description
- Stage and SSFs
- Treatment
- Text Documentation
- Other – includes FAC/ACC/SEQ and Class of Case
### 2014 FCDS DQIR (2012 Analytic Cases)

#### Sample Report

### Florida Cancer Data System - Facility Data Quality Indicator Report (DQIR) for 2012

**Analytic cases** (extracted 3/3/2014)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Goals</strong></td>
<td>Goals</td>
<td>Goals</td>
<td>Goals</td>
<td>Goals</td>
<td>Goals</td>
</tr>
<tr>
<td><strong>Facilities %</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Florida Facilities %</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Facilities %</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Florida Facilities %</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Facilities %</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Florida Facilities %</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Facilities %</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Florida Facilities %</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Demographics

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Analytic Cases</td>
<td>1,805</td>
<td>1,075,976</td>
<td>1,021</td>
<td>1,11,102</td>
<td>1,065</td>
</tr>
<tr>
<td>Sex Unknown (9)</td>
<td>&lt; 2%</td>
<td>0.000</td>
<td>0.033</td>
<td>0.037</td>
<td>0.000</td>
</tr>
<tr>
<td>Race not U.S., FCDS (96)</td>
<td>&lt; 3%</td>
<td>1.791</td>
<td>1.185</td>
<td>1.242</td>
<td>1.064</td>
</tr>
<tr>
<td>Race Unknown (99)</td>
<td>&lt; 3%</td>
<td>0.743</td>
<td>0.692</td>
<td>1.483</td>
<td>0.724</td>
</tr>
<tr>
<td>Ethnicity Unknown (9)</td>
<td>&lt; 1%</td>
<td>0.048</td>
<td>0.054</td>
<td>0.659</td>
<td>0.971</td>
</tr>
<tr>
<td>Birth Year Unknown</td>
<td>&lt; 1%</td>
<td>0.000</td>
<td>0.001</td>
<td>0.000</td>
<td>0.004</td>
</tr>
<tr>
<td>Birth Month Unknown</td>
<td>&lt; 1%</td>
<td>0.000</td>
<td>0.002</td>
<td>0.000</td>
<td>0.004</td>
</tr>
<tr>
<td>Birth Day Unknown</td>
<td>&lt; 1%</td>
<td>0.000</td>
<td>0.003</td>
<td>0.000</td>
<td>0.000</td>
</tr>
<tr>
<td>Birthplace US NOS/Unknown (998,999)</td>
<td>75.915</td>
<td>75.347</td>
<td>70.566</td>
<td>75.995</td>
<td>66.810</td>
</tr>
<tr>
<td>Primary Payer Unknown (99)</td>
<td>&lt; 3%</td>
<td>0.371</td>
<td>0.971</td>
<td>0.604</td>
<td>1.083</td>
</tr>
<tr>
<td>Marital Status Unknown (9)</td>
<td>1.144</td>
<td>2.112</td>
<td>1.043</td>
<td>2.095</td>
<td>1.501</td>
</tr>
<tr>
<td>Missing/Impossible SSN</td>
<td>&lt; 3%</td>
<td>2.050</td>
<td>2.343</td>
<td>3.130</td>
<td>1.944</td>
</tr>
<tr>
<td>Unaggregable (certainty 9)</td>
<td>&lt; 1%</td>
<td>0.000</td>
<td>0.165</td>
<td>0.056</td>
<td>0.180</td>
</tr>
<tr>
<td>FO Box (certainty 5)</td>
<td>0%</td>
<td>0.000</td>
<td>0.208</td>
<td>0.936</td>
<td>1.652</td>
</tr>
</tbody>
</table>

#### Diagnostic Confirmation

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Not Microscopically Confirmed (5-8)</td>
<td>&lt; 2%</td>
<td>5.464</td>
<td>0.401</td>
<td>7.249</td>
<td>0.462</td>
</tr>
<tr>
<td>DX Method Unknown (9)</td>
<td>&lt; 2%</td>
<td>0.053</td>
<td>0.172</td>
<td>0.055</td>
<td>0.179</td>
</tr>
</tbody>
</table>

#### Topography

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Other/Ill-Defined Sites (C76)</td>
<td>&lt; 1%</td>
<td>0.000</td>
<td>0.016</td>
<td>0.000</td>
<td>0.020</td>
</tr>
<tr>
<td>Unknown Primary Site (C809)</td>
<td>1.804</td>
<td>1.847</td>
<td>1.483</td>
<td>1.962</td>
<td>1.287</td>
</tr>
<tr>
<td>Morphology Non-Specific (0000-0005)</td>
<td>&lt; 3%</td>
<td>3.867</td>
<td>2.010</td>
<td>2.306</td>
<td>1.941</td>
</tr>
<tr>
<td>Grade Unknown (excludes C30.9)</td>
<td>39.204</td>
<td>36.274</td>
<td>40.802</td>
<td>33.958</td>
<td>40.804</td>
</tr>
</tbody>
</table>

#### Tumor Characteristics

|--------------------------|------|------|------|------|------|

---

*modified 3/3/14

---

1. Analytic according to FCDS (class of case: 0 - 22 or 54 - 42)
2. Percentage based on analytic cases of Florida residents at time of DX only.
2013 Call for Data – NPCR DER Summary

2013 Data Evaluation Reports
National Program of Cancer Registries
Cancer Surveillance System (National Data Quality)

Florida

Department of Health and Human Services
Centers for Disease Control and Prevention
Safer • Healthier • People
## Table 1: Submission Summary

<table>
<thead>
<tr>
<th>Diagnosis Year</th>
<th>Records Received</th>
<th>Non-reportable Records</th>
<th>Reportable Records</th>
<th>Invasive Records</th>
<th>In Situ Records</th>
<th>Benign Brain Records</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>112037</td>
<td>0</td>
<td>112037</td>
<td>102166</td>
<td>6540</td>
<td>3331</td>
</tr>
<tr>
<td>2009</td>
<td>119027</td>
<td>0</td>
<td>119027</td>
<td>108297</td>
<td>7345</td>
<td>3385</td>
</tr>
<tr>
<td>2008</td>
<td>116630</td>
<td>0</td>
<td>116630</td>
<td>106427</td>
<td>7313</td>
<td>3100</td>
</tr>
<tr>
<td>2007</td>
<td>1147891</td>
<td>0</td>
<td>1147891</td>
<td>104404</td>
<td>6606</td>
<td>3294</td>
</tr>
<tr>
<td>2006</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;= 2005 **</td>
<td>1147891</td>
<td>0</td>
<td>1147891</td>
<td>1085770</td>
<td>55807</td>
<td>6314</td>
</tr>
<tr>
<td>Prior to NPCR Reference Year</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>1727753</td>
<td>0</td>
<td>1727753</td>
<td>1613836</td>
<td>90860</td>
<td>23057</td>
</tr>
</tbody>
</table>

* Invasive records include in situ bladder.
** Includes all submitted records from the NPCR reference year through 2005.

Submission Date: November 29, 2011
NAACCR Record Version: 122
NPCR Record Version: 1995
NPCR Reference Year: 1995
Years Submitted: 1995-2011
### 2013 Call for Data – NPCR DER Summary

#### FCDS % Lower than NPCR Median %

<table>
<thead>
<tr>
<th>Category</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spanish/Hispanic Origin [190] Unknown</td>
<td></td>
</tr>
<tr>
<td>Birthplace Country [254] Unknown</td>
<td></td>
</tr>
<tr>
<td>DX Date [390] Month Blank</td>
<td></td>
</tr>
<tr>
<td>Topography [400] Other/Ill defined sites</td>
<td>(C76.0 - C76.8)</td>
</tr>
<tr>
<td>DX Confirmation [490] (Excludes DCO)</td>
<td>Not Microscopically Confirmed (5-8)</td>
</tr>
<tr>
<td>DX Confirmation [490] (Excludes DCO)</td>
<td>Unknown and Blank</td>
</tr>
<tr>
<td>Laterality [410] (paired organs only)</td>
<td>Unknown and Blank</td>
</tr>
<tr>
<td>RX Summ Surg Prim Site [1290] Blank and Unknown</td>
<td></td>
</tr>
<tr>
<td>RX Scope Reg LN Sur [1292] Blank and Unknown</td>
<td></td>
</tr>
<tr>
<td>Reason for No Surgery [1340] Blank and Unknown</td>
<td></td>
</tr>
<tr>
<td>RX Summ Radiation [1360] Blank and Unknown</td>
<td></td>
</tr>
<tr>
<td>RX Summ Chemo [1390] Blank and Unknown</td>
<td></td>
</tr>
<tr>
<td>RX Summ Hormone [1400] Blank and Unknown</td>
<td></td>
</tr>
<tr>
<td>RX Summ BRM [1410] Blank and Unknown</td>
<td></td>
</tr>
<tr>
<td>RX Summ Other [1420] Blank and Unknown</td>
<td></td>
</tr>
<tr>
<td>Rad Regional RX Modality [1570] NOS</td>
<td></td>
</tr>
<tr>
<td>Rad Regional RX Modality [1570] Blank and Unknown</td>
<td></td>
</tr>
<tr>
<td>RX Summ Transplnt/Endocr [3250] Blank and Unknown</td>
<td></td>
</tr>
<tr>
<td>Over-Ride Site/Type [2030] Overused</td>
<td></td>
</tr>
<tr>
<td>Date Last Contact [1750] (Decedents only)</td>
<td>Year Invalid</td>
</tr>
<tr>
<td>Cause of Death [1910] (Decedents only)</td>
<td>Death Cert Available No COD</td>
</tr>
<tr>
<td>Cause of Death [1910] (Decedents only)</td>
<td>Death Certificate Not Available</td>
</tr>
</tbody>
</table>
FCDS % Higher than NPCR Median %

- Birthplace Country [254] NOS
- Sequence Number Central [380] Two or More (01-35)
- Topography [400] Unknown Primary Site (C80.9)
- Morphology [420] Non-specific Neoplasms (8000-8005)
- Grade [440] (Excludes DCO) Unknown and Blank
- Laterality [410] (paired organs only) Only 1 side and Side NOS
- CS Extension [2810] Unknown
- CS Lymph Nodes [2830] Unknown
- CS Mets at DX [2850] Unknown
- Derived Summary Stage 2000 [3020] Unknown/Unstaged
- RX Summ Surg Prim Site [1290] Surgery NOS
- RX Summ Surg Oth Reg/Dis [1294] Blank and Unknown
- RX Summ Surg/Rad Seq [1380] Blank and Unknown
- RX Summ Systemic/Sur Seq [1639] Blank and Unknown
- Over-Ride Age/Site/Morph [1990] Overused
- Over-Ride SeqNo/DxConf [2000] Overused
- Over-Ride Site/Lat/SeqNo [2010] Overused
- Over-Ride Histology [2040] Morphology Type and Behavior
- Over-Ride Site/Lat/Morph [2074] Overused
- Census Tr Cert 2000 [365] Unknown
- Follow-up Source [1790] Blank
2014 Grade Coding Instructions
ICD-O-3 Updates

IMPLEMENTATION TIMELINE(S)
2014 FCDS DAM APPENDIX
HANDBOUTS

FCDS ANNUAL CONFERENCE
ORLANDO, FL
7/25/2014

STEVEN PEACE, CTR
Grade Coding Instructions 2014+

Instructions for Coding Grade for 2014+

GRADE, DIFFERENTIATION OR CELL INDICATOR
Same weight 1
NAACCR Item # 440
NAACCR Name: Grade
differentiation or cell indicator. Solid tumors (codes 1, 2, 3, 4, 5, 6, 7, 8, 9)
Note: These instructions pertain to the data item Grade, Differentiation or Cell Indicator.
These are coding instructions for cases diagnosed 1/1/2014 and forward.

Hematopoietic and Lymphoid Neoplasms
Cell indicator (codes 5, 6, 7, 8, 9)
Cell indicator (codes 5, 6, 7, 8, 9) describes the lineage or phenotype of the cell. Codes 5, 6, 7, and 8 are used only for hematopoietic and lymphoid neoplasms. Code 9 indicates cell type not determined, not stated, or not applicable.

Coding Grade for Hematopoietic and Lymphoid Neoplasms
1. Determine the histology based on the current Hematopoietic and Lymphoid Neoplasm Manual
   [http://user.cancer.gov/tools/hema/hematopoietic_instructions_and_index]
2. Determine the cell indicator by applying the “Grade of tumor tables” within the current Hematopoietic and Lymphoid Neoplasm Manual
   [http://user.cancer.gov/tools/hema/hematopoietic_instructions_and_index] to code the grade.

<table>
<thead>
<tr>
<th>Grade Code for Hematopoietic and Lymphoid Neoplasms</th>
<th>Grade Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>BC-0, BC-1; BC-preservative</td>
<td>5</td>
</tr>
<tr>
<td>BC-0, BC-1; BC-preservative</td>
<td>5</td>
</tr>
<tr>
<td>Null cell, non-fusion</td>
<td>7</td>
</tr>
<tr>
<td>Null cell, non-fusion</td>
<td>7</td>
</tr>
<tr>
<td>NK cell, natural killer cell</td>
<td>8</td>
</tr>
<tr>
<td>NK cell, natural killer cell</td>
<td>8</td>
</tr>
<tr>
<td>Grade unknown, not stated, not applicable</td>
<td>9</td>
</tr>
</tbody>
</table>

Solid Tumors
grade, differentiation (codes 1, 2, 3, 4, 5, 6, 7, 8, 9)
Pathologic examination determines the grade, or degree of differentiation, of the tumor. For these cancers, the grade is a measurement of how closely the tumor cells resemble the parent tissue (organ of origin). Well-differentiated tumor cells closely resemble the tissue from the organ of origin. Poorly differentiated and undifferentiated tumor cells are disorganized and abnormal looking; they bear little

http://user.cancer.gov/tools/grade/ 1 of 3

North American Association of Central Cancer Registries, Inc.

GUIDELINES FOR ICD-O-3 UPDATE
IMPLEMENTATION
Effective January 1, 2014

Prepared by the
NAACCR ICD-O-3 Update Implementation Work Group

December 1, 2013
Introduction to Coding Grade for 2014+

- The coding of grade has become complicated over time with the introduction of specialized site-specific grading systems and changes to coding instructions for some cancer sites.


- The Consensus Technical Work Group drafted a new set of instructions for 2014 forward that were simpler and the same for CoC, SEER, and NPCR.

- These consensus instructions differ from all previous instructions.

- Site-Specific Grade will continue for some cancer sites similar to SSF grades.
Introduction to Coding Grade for 2014+

- New Instructions Found @ [http://seer.cancer.gov/tools/grade](http://seer.cancer.gov/tools/grade)

- CoC, NPCR, SEER and FCDS will implement for all cases 2014+

- FCDS has included full set of new instructions in 2014 FCDS DAM

- No New Codes Added and No Codes Deleted

- Some grade values may be derived from SSF grade fields

- Prostate Grade and Gleason Cross-Walk to Grade is Significant
DO NOT GO BACK TO OLD CASES TO CHANGE OR CORRECT

- Code highest invasive tumor grade – even if just a focus
- Do not code grade from metastatic site or recurrent tumor – primary site only
- Do not code grade from tissue post chemo/xrt/brm/horm – tx may alter grade
  - Includes post neoadjuvant surgical specimen – do not code post neoadjuvant tx

- Instructions allow coding grade for non-invasive tumors – most are 2-grade
  - 2 grade system = code 2 (low grade)
  - 2 grade system = code 4 (high grade)

- BUT – if both in-situ and invasive – code the grade of the invasive tumor only!

- Gleason Conversion now same as what appears in AJCC 7th edition
  - Caution: Gleason 5, 6, 7 has changed over the years – use table
  - Gleason 10 is not = 4 (undifferentiated) – use table
Coding Grade for Solid Tumors - General

- Code grade of primary tumor only
- Code the highest grade recorded – even if it is only a focus
- Do not code grade based on metastatic or recurrent tissue sample
- Do not code grade based on tissue sample obtained after start of any TX
  - NOTE: This is particularly important for cases with surgery following neoadjuvant therapy

- C80.9 – Unknown Primary – Grade Must = 9
- C76.0-C76.8 – Other and Ill-Defined Sites – Grade Must = 9
- Body System, NOS Codes – Grade Must = 9 (no primary site)

- Non-Invasive/In-Situ Neoplasm – path may state grade – not same as invasive grade – BUT, can be coded – Do NOT code grade of dysplasia

- Invasive and Non-Invasive – code grade of invasive component ONLY!
Analysis of Prostate Grade Prior to 2014
Based Solely on the Grade Field
Is NOT Recommended – WHY?

<table>
<thead>
<tr>
<th>Description</th>
<th>Grade Code</th>
<th>AJCC 7th</th>
<th>SEER 2003-2013</th>
<th>AJCC 6th</th>
<th>SEER &lt; 2003</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gleason Score</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>G1</td>
<td>G1</td>
<td>G1</td>
<td>G1</td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>G1</td>
<td>G1</td>
<td>G1</td>
<td>G1</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>G1</td>
<td>G1</td>
<td>G1</td>
<td>G1</td>
</tr>
<tr>
<td>5</td>
<td>1</td>
<td>G1</td>
<td>G2</td>
<td>G2</td>
<td>G2</td>
</tr>
<tr>
<td>6</td>
<td>1</td>
<td>G1</td>
<td>G2</td>
<td>G2</td>
<td>G2</td>
</tr>
<tr>
<td>7</td>
<td>2</td>
<td>G2</td>
<td>G3</td>
<td>G3</td>
<td>G2</td>
</tr>
<tr>
<td>8</td>
<td>3</td>
<td>G3</td>
<td>G3</td>
<td>G3</td>
<td>G3</td>
</tr>
<tr>
<td>9</td>
<td>3</td>
<td>G3</td>
<td>G3</td>
<td>G3</td>
<td>G3</td>
</tr>
<tr>
<td>10</td>
<td>3</td>
<td>G3</td>
<td>G3</td>
<td>G3</td>
<td>G3</td>
</tr>
</tbody>
</table>
Coding Grade - Prostate

Use highest Gleason score from biopsy/TURP/prostatectomy
Use a known value over an unknown value.
Exclude results from tests performed after neoadjuvant therapy.

Gleason Grade Conversion Table

<table>
<thead>
<tr>
<th>Code</th>
<th>Gleason's Score</th>
<th>Terminology</th>
<th>Histologic Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2, 3, 4, 5, 6</td>
<td>Well Differentiated</td>
<td>I</td>
</tr>
<tr>
<td>2</td>
<td>7</td>
<td>Moderately Differentiated</td>
<td>II</td>
</tr>
<tr>
<td>3</td>
<td>8, 9, 10</td>
<td>Poorly Differentiated</td>
<td>III</td>
</tr>
</tbody>
</table>

CAUTION: Gleason 5, 6, 7 have changed over the years
Gleason 10 is never Grade = 4
Introduction to ICD-O-3 Updates

- History of ICD-O
  - 1976 – ICD-O
  - 1990 – ICD-O-2
  - 2000 – ICD-O-3
    - 2001 Errata
    - 2003 Errata
    - 2011 Updates
    - ICD-O-3.1 On-Line - IARC
  - Languages: Chinese, Czech, English, Finnish, Flemish/Dutch, French, German, Japanese, Korean, Portuguese, Spanish, Romanian, Turkish

Guidelines for ICD-O-3 Update Implementation
Effective January 1, 2014

Prepared by the
NAACCR ICD-O-3 Update Implementation Work Group

December 1, 2013
Introduction to ICD-O-3 Updates

- What drives the timing of ICD-O-3 Updates?
- Why has U.S. delayed implementing the 2011 updates?
- What do the 2011 updates include?
- What do the updates NOT include?
- What if we encounter a “new histology” before implementation?
- How do you use the interim cross-walk to ICD-O-3?
- When will the next updates be published?
- When will the next updates be implemented in the U.S.?
What is Changing for 2015?

Why Can’t We Just Start Using the New ICD-O-3 Codes in 2015?

Interim Cross-Walk
### Why Delay? -- The Impact of ICD-O-3 Updates

1. Changes to Legislation Required in Some States
2. Volume II Reportable Case Matrix (high grade dysplasia for GI cancers)
4. SEER Site/Type Table Update
5. MPH Rules Solid Tumors
6. MPH Rules Hematopoietic/Lymphoid Neoplasms
7. Standard EDITS and State-Specific EDITS
8. AJCC/TNM – Histology Inclusion Tables and Histology-Driven Chapters
9. Collaborative Stage Data Collection – Histology Inclusion Tables
10. Collaborative Stage Data Collection – any special SSFs included/excluded
11. FORDS/SEER/State Coding Manual Updates
12. CoC Site-Specific Surgery Codes – Histology-Driven “Sites”
13. Automated/Manual Tumor Consolidation Histology Pairs Tables
14. SEER Incidence Site Recode ICD-O-3 –Histology-Driven Recodes
15. SEER Lymphoma Subtype Recodes – Histology-Driven Recodes
16. International Classification of Childhood Cancer (ICCC) Recodes
17. Histology Code Conversion(s) if any are required
18. Software-related: Site/Histo grouping updates as required where available for ad-hoc reports
19. Software-related: Updates to scoped lookups (based on site/histo)
20. Revisions: Does that include codes being added, deleted, converted?
21. Registry Plus Online Help resource
What do you do in the interim for coding?

- Call FCDS if you have a question
- Use the ICD-O-3 Cross-Walk for new-to-old codes
- Do not try to enter new ICD-O-3 codes until implemented
- Do not try to force the stated histology into a code that doesn’t apply

- Consider adding a local-use data item to store new codes until guidance on implementation provides instruction about how to code and if you need to go back to identify older cases that can be recoded after implementation

- If pathologist terminology is specific but there is not a specific ICD-O-3 code (whether it is in the 2011 Update or NOT), you must code to a less specific ICD-O-3 code even if it is NOS code.

- Be consistent with your coding – you and your staff

- Clearly Document new terminology used by pathologist in the pathology text area for future reference – this allows you to find the case for possible recode in future once rules have been established, codes approved, etc.
NEW RULES AND INSTRUCTIONS
NEW LOOK FOR DATABASE
HOW TO USE

FCDS ANNUAL CONFERENCE
ORLANDO, FL
7/25/2014

STEVEN PEACE, CTR
Hematopoietic and Lymphoid Neoplasm Coding Manual

Effective with Cases Diagnosed 1/1/2010 and Forward

Published January 2014

Editors: Jennifer Ruhl, MSHCA, RHIT, CCS, CTR, NCI SEER
         Margaret (Peggy) Adamo, BS, AAS, RHIT, CTR, NCI SEER
         Lois Dickie, CTR, NCI SEER
         Leon Sun, MD, CTR, NCI SEER

Developer/consultant: Carol Hahn Johnson, BS, CTR, Consultant

Where to Locate the Manual and Database

Web-based Version of the Database
The Heme DB provided in a web-based format has several benefits over the software version:

- Updates are automatic: users do not have to install anything to access the latest revisions.
- Allows access from any computer or device with an Internet connection.
- Eliminates problems for users who do not have permission to install software on their work computers.

Information from the 2010 and 2012 databases has been consolidated into one database and all information for cases diagnosed from 2010 and forward is contained in this one database. There are also entries for some obsolete terms that were in effect for cases diagnosed 2001–2009. These entries are clearly marked as Obsolete.

_Hematopoietic and Lymphoid Neoplasm Database and Coding Manual_ – For cases diagnosed January 1, 2010 and later.

Stand-alone Version of the Database
The stand-alone version of the database also contains the information from the 2010 and 2012 databases consolidated into one database. The web-based version of the Heme DB is the preferred method to access the current data. If you need the stand-alone version because of limited Internet access, it is still available for now, but may be phased out in the future. Note that the information in the stand-alone version of the database may not be as current as the web-based version. A new feature will soon be implemented to update the Heme data in the stand-alone version automatically whenever you have an Internet connection. An e-mail will be sent out when this new feature is available.

[Download the Hematopoietic Database Software Version 2.3.1](#) (released January 21, 2014)
Major Changes

- 2014 Updates are effective for all cases 1/1/2010 >

- Review of cases abstracted using older version(s) is not required;

- However, for those who choose to review cases already abstracted using an older version – Please refer to soon-to-be-published change documents that will be available on SEER Website in the near future.

- Revised manual effective for cases 1/1/2010 forward
  - There will no longer be a different “Version” based on Dx Year
  - “Published Date” will be used as reference instead of “Version”
    - Published January 2014
  - 2010 and 2012 Versions of Database and Manual no longer available
  - The option to switch between 2010 and 2012 versions was removed
Major Changes

- OBSOLETE CODES ARE INVALID for All Cases 1/1/2010
  - All ICD-O [obs] and (OBS) codes are obsolete as of 1/1/2010
    - EDITS have not completely caught up with new[obs] rules
  - Search and Re-Direct for OBS codes are now date driven

- Instruction for abstracting or creating “DCO, path-only and minimal information” cases was removed from the database

- Working on how to “fix” cases already coded using OBS codes
Hematopoietic Database Changes

Users Guide for NCI’s Online Hematopoietic and Lymphoid Database

Table of Contents

What’s New in the Hematopoietic and Lymphoid Database ......................................................... 1
Home Page ................................................................................................................................. 2
Searching the Database ........................................................................................................... 3
Multiple Primaries Calculator .................................................................................................... 4
Using the ICD Code Lists .......................................................................................................... 5
Viewing the information for a Specific Disease .......................................................................... 6
Viewing the information for an Obsolete Disease .................................................................... 9

Figure 1 – Hematopoietic and Lymphoid Database Home Page

When the Hematopoietic and Lymphoid database opens the search field is blank, all of the entries in
the database appear under the ICD-O-3 and Morphology and Name columns. When the user highlights
a disease, the Disease Information page opens.

1. The breadcrumbs appear at the top of each page of the Hematopoietic and Lymphoid database,
telling you where you are on the website.

2. The ICD-O-3 Code Lists, ICD-O-3 Code Lists page. From that page you can select the ICD-O Code
List you want to display. (See the section Using ICD Code Lists for more information.)

3. To open the Multiple Primaries Calculator, click on the link on the upper left side of the screen. The
calculator contains the codes, as long as the latest diagnostic year of one of the codes is 2010 or
later, to determine whether they represent the same primary or a new primary.

4. The database search field and search button are above the icd-o-5 and morphology and name title
bar (see). (See the section searching the database for more information.)

5. The number of the disease in the database appears above the title bar for the icd-o-5 and
Morphology and Name. When a search has been run, this number becomes the number of results
for that search.

6. The title bar for the ICD-O-3 and Morphology and Name. The diseases can be sorted by ICD-O-3
code or name in descending order (down arrow) or ascending (up arrow) order by clicking on the
title by which you want to search. The arrow toggles between up or down by clicking again.

7. The ICD-O-5 and Morphology column holds the ICD-O-5 and morphology codes for each disease on
the list.

8. The names of each disease appear in the Name column.

9. Indication that a disease has been declared obsolete. (See Viewing the Information for an Obsolete
Disease.)
Hematopoietic Database Changes

Searching the Database

1. Enter terms for the search in the Search field.
2. Click the Search button to run an "and" search. An "and" search treats multiple terms as if there is an "and" between each term. Every term that appears in the search string must also appear in every result.
3. Click the Refine option to refine the search. The "or" search results will appear and the link will change to disease matches all terms which will take the user back to the "and" search results. An "or" search treats multiple terms as if there is an "or" between each search term. In the example above, either the word "chronic" or the word "leukemia" must appear in every result.
4. Click on the red X to reset the search to blank. The results will include all database entries.

The Hematopoietic and Lymphoid Database search function follows these rules:
- Search terms are not case-sensitive so you can enter them in any case.
- To search for exact terms in a precise order, use quotation marks (e.g., "term terms").
- All search terms are highlighted in the Results column and the Disease Information column.
- The search is weighted and the default is to sort the results based on Relevance by weight, but the column headers allow the user to sort the results by relevance, name, or ICD-0-3 code, either ascending or descending, simply by clicking on the column header.

Viewing the Information for a Specific Disease

Each disease now has its own page and URL, which makes it possible to bookmark any disease information pages that you use regularly.

Figure 2 - Search Screen

- Reference: ICD-0-3 Morphology
- Name: Acute lymphoblastic leukemia
- Disease Information: Acute lymphoblastic leukemia
- ICD-0-3 Morphology: 9541.1
- ICD-0-3 Morphology: 9541.1
- Primary site: Lymph node
- Reasonable: Acute lymphoblastic leukemia
- Code: 9541.1

Figure 6 - Disease Information Page

1. Name of the disease on the Disease Information Page.
2. Codes and effective data ranges for all of the ICD-0-3 morphologies (if available).
3. The years the disease was reportable.
4. Primary site code.
5. Diagnosis year drop-down menu for coding the disease. (See Figure 7.)
6. Link to the Coding Manual for this year of the diagnosis.
Hematopoietic Database Changes

Figure 7 – Year of Diagnosis Dropdown Menu

The dropdown menu for selecting the year for diagnosis may include years where there is no information available in the database, other than the information above the diagnosis year dropdown menu. A double hyphen appearing before and after a year (e.g. –1995–) indicates that information such as description and abstractor notes for that year of diagnosis for that disease is not currently available in the database.
Surgery Coding Refresher and Review of Instructions for Coding Scope Reg LN Surg

PROBLEM SITE-SPECIFIC SURGERY CODES
CLARIFICATIONS FOR CODING
SCOPE OF REGIONAL LYMPH NODE SURGERY

FCDS ANNUAL CONFERENCE
ORLANDO, FL
7/25/2014

STEVEN PEACE, CTR
Surgery Coding Refresher - Outline

- First Course of Treatment
- What is Surgical Treatment
- Coding Multiple Surgery Fields
- Problematic Site-Specific Surgery Codes
  - Colon
  - Breast
  - Lymphoma
  - Ovary vs. Female Peritoneum

- Coding Scope of Regional Lymph Node Surgery
  - Sentinel Node(s) Biopsy or Excision
  - Regional Lymph Node Dissection
  - Sentinel Node(s) + Regional Lymph Node Dissection
  - Resection of Distant Lymph Node(s)

Source: WPA Poster US Public Health Service and American Society for the Control of Cancer 1941
Principles of Surgery

- Establish a diagnosis
- Remove primary tumor
- Evaluate regional extent of disease
- Surgical management of metastatic disease

- Appropriateness of surgery for type of neoplasm
- Appropriateness of surgery and clinical stage at Dx
- Appropriateness of surgery given patient factors
- Appropriateness of surgery given tumor factors

- Weighing the treatment options
- Informed Consent and Patient Choice
- Conservative versus radical surgical approach
- Reconstruction as part of first course of treatment
## Coding Multiple Surgery Fields

### CoC FORDS Surgery Fields
- Date of First Surgical Procedure
- RX Date – Surgery Flag
- Date Most Definitive Surg - Prim Site
- RX Date – Most Definitive Surg Flag
- Surg Proc - Primary Site
- Surg Proc - Primary Site – This Facility
- Approach – Surg Prim Site This Fac
- Surgical Margins – Primary Site
- Scope Reg LN Surg
- Scope Reg LN Surg – This Facility
- Surg Proc – Other Site
- Surg Proc – Other Site – This Facility
- Date Surg Discharge
- RX Date Surg Discharge Flag
- Reason for No Surgery of Primary Site
- Radiation/Surgery Sequence
- Systemic/Surgery Sequence

### Central Registry Surgery Fields
- Date of First Surgical Procedure
- RX Date – Surgery Flag
- RX Summ – Surg Prim Site
- Reason for No Surgery of Primary Site
- RX Summ – Scope Reg LN Surgery
- RX Summ – Surgery OtherReg/Distant Site
- RX Summ – Radiation/Surgery Sequence
- RX Summ – Systemic/Surgery Sequence
When multiple first course surgical procedures are included under the same surgery item, the most extensive surgery is usually the last surgery performed.

The code represents the cumulative effect of the separate surgical procedures.

- **Surg Prim Site** – the most extensive surgical procedure of the primary site (includes local tumor destruction, surgical excision or resection of the primary site, resection plus reconstruction of the primary site, and surgical resection of the primary site plus any surrounding tissues or organs removed in continuity with the primary site – en bloc resection)

- **Scope of Regional LN Surgery** – biopsy, aspiration or removal of sentinel lymph node(s) and/or surgical excision/resection of other regional lymph nodes that drain the primary site – may include 1 or more procedures – the LN “removal” may be for diagnostic, staging and/or treatment of disease.

- **Surgery of Other Sites** – surgical removal of distant lymph node(s) and/or regional and/or distant tissue or organs beyond primary site or regional LN
Surgery of Primary Site - Colon

**COLON**
C18.0–C18.9
(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

**Code** removal/surgical ablation of single or multiple liver metastases under the data item *Surgical Procedure/Other Site* (NAACCR Item #1294).

**Codes**

00 None; no surgery of primary site; autopsy ONLY  
10 Local tumor destruction, NOS  
11 Photodynamic therapy (PDT)  
12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)  
13 Cryosurgery  
14 Laser

No specimen sent to pathology from surgical events 10–14.

20 Local tumor excision, NOS  
21 Photodynamic therapy (PDT)  
22 Electrocautery  
23 Cryosurgery  
24 Laser ablation  
25 Laser excision  
26 Polypectomy, NOS  
27 Excisional biopsy  
28 Polypectomy-endoscopic  
29 Polypectomy-surgical excision  

Any combination of 20 or 26–29 WITH:  
21 Photodynamic therapy (PDT)  
22 Electrocautery  
23 Cryosurgery  
24 Laser ablation  
25 Laser excision

http://hopkinscoloncancercenter.org
Surgery of Primary Site - Colon

30 Partial colectomy, segmental resection
   32 Plus resection of contiguous organ; example: small bowel, bladder

40 Subtotal colectomy/hemicolectomy (total right or left colon and a portion of transverse colon)
   41 Plus resection of contiguous organ; example: small bowel, bladder

50 Total colectomy (removal of colon from cecum to the rectosigmoid junction; may include a portion of the rectum)
   51 Plus resection of contiguous organ; example: small bowel, bladder

60 Total proctocolectomy (removal of colon from cecum to the rectosigmoid junction, including the entire rectum)
   61 Plus resection of contiguous organ; example: small bowel, bladder

70 Colectomy or coloproctotectomy with resection of contiguous organ(s), NOS (where there is not enough information to code 32, 41, 51, or 61)
   **Code 70 includes:** Any colectomy (partial, hemicolecction, or total) WITH a resection of any other organs in continuity with the primary site. Other organs may be partially or totally removed. Other organs may include, but are not limited to, oophorectomy, partial proctectomy, rectal mucosectomy, or pelvic exenteration.

80 Colectomy, NOS
Surgery of Primary Site - Breast

BREAST
C50.0–C50.9
(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9952)

Codes
00  None; no surgery of primary site; autopsy ONLY
19  Local tumor destruction, NOS

No specimen was sent to pathology for surgical events coded 19 (principally to January 1, 2003).

20  Partial mastectomy, NOS, less than total mastectomy, NOS
    21  Partial mastectomy WITH nipple resection
    22  Lumpectomy or excisional biopsy
    23  Reexcision of the biopsy site for gross or microscopic residual disease
    24  Segmental mastectomy (including wedge resection, quadrantectomy, tylectomy)

Procedures coded 20-24 remove the gross primary tumor and some of the breast tissue (breast-conserving or preserving). There may be microscopic residual tumor.

30  Subcutaneous mastectomy
A subcutaneous mastectomy, also called a nipple sparing mastectomy, is the removal of breast tissue without the nipple and areolar complex or overlying skin. It is performed to facilitate immediate breast reconstruction. Cases coded 30 may be considered to have undergone breast reconstruction.
Surgery of Primary Site - Breast

40  Total (simple) mastectomy

41  WITHOUT removal of uninvolved contralateral breast

43  With reconstruction NOS

44  Tissue

45  Implant

46  Combined (Tissue and Implant)

42  WITH removal of uninvolved contralateral breast

47  With reconstruction NOS

48  Tissue

49  Implant

75  Combined (Tissue and Implant)

A total (simple) mastectomy removes all breast tissue, the nipple, and areolar complex. An axillary dissection is not done, but sentinel lymph nodes may be removed.

For single primaries only, code removal of the involved contralateral breast under the data item Surgical Procedure/Other Site (NAACCR Item #1294) and/or Surgical Procedure/Other Site at This Facility (NAACCR Item #674).

If the contralateral breast reveals a second primary, each breast is abstracted separately. The surgical procedure is coded 41 for the first primary. The surgical code for the contralateral breast is coded to the procedure performed on that site.

Reconstruction that is planned as part of first course treatment is coded 43-49 or 75, whether it is done at the time of mastectomy or later.
Most Common Error: When a lymph node is biopsied or removed only to diagnose or to stage a lymphoma – to assess the patient status and confirm the lymphoma - do not code the lymph node removal as surgical treatment for lymphoma – this is a biopsy only to confirm the presence or absence of disease.
Surgery of Primary Site - Extranodal Lymphoma

http://commonsensehealth.com

Surgery of Primary Site - Ovary

Surgery of Primary Site

Codes
00 None; no surgery of primary site; autopsy ONLY
17 Local tumor destruction, NOS
No specimen sent to pathology from surgical event 17.
23 Total removal of tumor or (single) ovary, NOS
26 Resection of ovary (wedge, subtotal, or partial) ONLY, NOS; unknown if hysterectomy done
27 WITHOUT hysterectomy
28 WITH hysterectomy
No specimen sent to pathology from surgical events 25-28.
35 Unilateral (salpingo-) oophorectomy; unknown if hysterectomy done
36 WITHOUT hysterectomy
37 WITH hysterectomy
[NOTE: Use code 37 for current unilateral (salpingo-) oophorectomy with previous history of hysterectomy]
50 Bilateral (salpingo-) oophorectomy; unknown if hysterectomy done
51 WITHOUT hysterectomy
52 WITH hysterectomy
[NOTE: Use code 52 for current bilateral (salpingo-) oophorectomy with previous history of hysterectomy]
55 Unilateral or bilateral (salpingo-) oophorectomy WITH OMENTECTOMY, NOS; partial or total; unknown if hysterectomy done
56 WITHOUT hysterectomy
57 WITH hysterectomy
Debunking: cytoreductive surgery, NOS
58 WITH colon (includes appendix) and/or small intestine resection (not incidental)
61 WITH partial resection of urinary tract (not incidental)
63 Combination of 61 and 62
Debunking is a partial or total removal of the tumor mass and can involve the removal of multiple organ sites. It may include removal of ovaries and/or the uterus (a hysterectomy). The pathology report may or may not identify ovarian tissue. A debunking is usually followed by another treatment modality such as chemotherapy.

http://ovarydisease.com
Surgery of Primary Site – Female Peritoneum

ALL OTHER SITES
C14.2-C14.8, C17.0-C17.1, C23.9, C24.0-C24.9, C25.0-C25.9, C30.0-C30.1, C31.0-C31.9, C33.9, C38.0-C38.8, C39.0-C39.8, C48.0-C48.8, C51.0-C51.9, C52.9, C57.0-C57.9, C58.9, C60.0-C60.9, C63.0-C63.9, C68.0-C68.9, C69.0-C69.9, C74.0-C74.9, C75.0-C75.9
(Except for M-9727, 9738, 9741-9742, 9704-9809, 9832, 9840-9931, 9945-9946, 9950-9956, and 9975-9992)

SURGERY OF PRIMARY SITE

Codes:
00 None; no surgery of primary site, autopsy ONLY
10 Local tumor destruction, NOS
11 Photodynamic therapy (PDT)
12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
13 Cryosurgery
14 Laser

No specimen sent to pathology from surgical events 10.14

20 Local tumor excision, NOS
26 Polypectomy
27 Excisional biopsy
Any combination of 20 or 26-27 WITH
21 Photodynamic therapy (PDT)
22 Electrocautery
23 Cryosurgery
24 Laser ablation
25 Laser excision

Specimen sent to pathology from surgical events 20-27.

30 Simple/partial surgical removal of primary site
40 Total surgical removal of primary site: enucleation
41 Total enucleation (for eye surgery only)
50 Surgery stated to be “debulking”

60 Radical surgery
Partial or total removal of the primary site WITH a resection in continuity (partial or total removal) with other organs.
Sentinel lymph node biopsy increasingly valuable tool for treatment planning

Easy method to identify early lymph node metastasis at 1st node(s) station

Clinically early stage cancers benefit from sentinel lymph node biopsy

Clarification document published on 3/9/2012, BUT...

Investigators still raising concerns regarding validity of coding of this data item
  - Significant under-reporting of sentinel lymph node biopsies
  - Significant incorrect coding of Scope of Regional LN Surgery
  - Registrars still not following the instructions from 3/9/2012
  - SLNBx are most often performed for breast and skin cancers

Confusion continues for registrars on how to correctly code item

Vendors may be incorrectly mapping multiple LN surgical procedures when software allows every procedure to be coded separately >> algorithm = derived
Coding Scope of Regional Lymph Node Surgery

- Scope of Regional Lymph Node Surgery is defined as; “the removal, biopsy, or aspiration of regional lymph node(s) at the time of surgery of the primary site or during a separate surgical event.
  - Collected for each surgical event even if surgery of primary site not performed
  - Record any surgical procedures which aspirate, biopsy or remove regional lymph nodes in an effort to diagnose and/or stage the patient’s disease
  - Combinations of both SLNBx (FNA or excisional) plus regional lymph node dissection occur when sentinel lymph node biopsy shows evidence of neoplasm
  - Codes 0-7 are hierarchical. If only 1 procedure can be recorded, code the procedure that is numerically higher.
  - Review the operative report to confirm whether an aspiration or excision of regional lymph nodes was performed plus or minus additional node dissection
  - Sometimes SLNBx is attempted but no nodes map and/or none removed – when this happens, the patient normally moves on to a full node dissection – code the sentinel node biopsy as having been performed PLUS the node dissection.
  - When 5 or more nodes are examined by pathologist – probably node dissection and not a sentinel node biopsy – the sentinel node biopsy usually is 1 or 2 nodes only
  - Do NOT USE the items #LN+ and #LNexamined as means to determine the code
Sentinel Lymph Node(s) - Biopsy

- Sentinel Lymph Node(s) are:
  - First node(s) to receive lymphatic drainage from the primary tumor
  - First node(s) to which tumor will metastasize – bx with FNA or excise
  - When sentinel node(s) negative for tumor (FNA or excision) then other nodes in the primary site regional nodal basin also likely to be negative
  - Reduces unnecessary surgery and complications from surgery removing all nodes from the nodal basin
Current standards of care for melanoma and breast indicate patients with 1 or more positive sentinel lymph node(s) should undergo full regional node dissection.

Many studies comparing SLNBx to full nodal bed dissection conclude SLNBx prevents unnecessary short and/or long term complications and comorbidities in patients with negative nodes.

SLNBx Methodology and Surgical Practice Guidelines continue to evolve – particularly when micrometastasis is identified – is the presence (or absence) of micrometastasis significant or not?

Do you include nodes with micrometastasis as positive lymph node(s)?
Risks and Side Effects of Node Dissection

- SLNBx is not recommended for clinically positive nodes or when the primary tumor is large and/or ulcerated or if disseminated disease
- Node dissection costs more than SLNBx or FNA of lymph node in terms of procedure, where procedure can be performed, follow-up, other risk
- Risk post-operative range of motion limitations in lymph drainage area
- Risk of lymphedema is higher with a node dissection
- Risk of numbness of skin in lymph drainage area
- Scarring is more extensive with node dissection
- Risk of infection higher with node dissection
- Risk increases with obesity
Recurring Issues and Problem Areas for Florida Registrars

Numerous Discussion Topics
See Detailed List

FCDS Annual Conference
Orlando, FL
7/25/2014

Steven Peace, CTR
Please Use Current Desk References

- 2014 FCDS DAM plus LVI Errata
- ICD-O-3 plus 3 errata and the 2011 updates
- Do not use ICD-O-3 to code heme/lymph
- SEER*Rx
  - On-Line Version – BEST
  - Desktop Version – version 2.2.0
- 2007 MPH Rules for Solid Tumors
  - 2012 Updated Version
- 2014 Hematopoietic and Lymphoid Neoplasm
  - 2014 Database – Neoplastic Details and Abstractor Notes
  - On-Line Version – BEST
  - Desktop Version – version 2.3.1
- Collaborative Stage Data Collection System v02.05
- CoC FORDS – not updated for 2014
- SEER 2014 Coding and Staging Manual
- NCCN Guidelines – current year version
Social Security Number (SSN)

- Why is Social Security Number so important?

- Why isn’t SSN with patient registration anymore?

- Are you sure we still get SSN – it isn’t showing up in my software
  - AHCA requires SSN also – it is the only patient identifier besides DOB provided
  - EMR may prevent SSN from automatically populating into the registry software
  - Problems with cross-walks and updates when auto-populating demographics

- How do I gain access to the SSN in the EMR? Billing Systems

- What about SSN EDITS? Can they be overridden?

- When should I use 9999999999? Can I enter just the last 4-digits?
Make time to ponder the little things in life.
Lymph Vascular Invasion

LYMPH- VASCULAR INVASION

NAACCR ITEM #1182

Lymph-vascular invasion or LVI indicates the presence or absence of tumor cells in small lymphatic channels (not lymph nodes) or small blood vessels within the primary tumor or in the surrounding tissues of the primary site as noted microscopically by the pathologist. When a neoplasm shows the presence of lymph-vascular invasion, tumor cells have broken free of the primary tumor and now have the ability to float throughout the body. Therefore, lymph-vascular invasion may be used an indicator of prognosis.

Benign, borderline and in-situ neoplasms cannot have lymphatic or vascular invasion by definition. When any invasion is present, the neoplasm is classified as malignant with behavior = 3.

Lymphoid and myeloid neoplasms (neoplasms that originate in the lymphatic system, bone marrow, or in circulating blood) cannot have lymphatic or vascular invasion. Only solid tumors may have LVI.

Lymphatic invasion is not the same as involvement of regional lymph nodes.

Lymph-vascular invasion does not include perineural invasion.

Coding Instructions
1. The primary source of this information is the pathology report or a physician’s statement.
2. Use code 0 when behavior = 0, 1, or 2 (ALL benign, borderline, and in-situ neoplasms)
3. Use code 0 when the pathology report states that no lymph-vascular invasion was identified.
4. Use code 1 when lymph-vascular is identified anywhere in a primary tumor specimen.
5. Use code 8 when histology = 9590-9992 (ALL lymphoid and myeloid neoplasms).
6. Use code 9 if the pathology report indicates that the presence of lymph-vascular invasion could not be determined or when no information is available in the pathology report or medical record.
7. Use code 9 when no tissue from the primary site was examined (invasive solid tumors only).
## Thyroid Cancer: I-131 and Hormone Therapy

### Thyroid cancer in the U.S.

An estimated 534,973 people live with thyroid cancer in the U.S. New cases and deaths per 100,000 Americans:

<table>
<thead>
<tr>
<th>Year</th>
<th>New Cases</th>
<th>Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>'92</td>
<td>5.9</td>
<td>0.5</td>
</tr>
<tr>
<td>'94</td>
<td>6.1</td>
<td>0.4</td>
</tr>
<tr>
<td>'96</td>
<td>6.5</td>
<td>0.5</td>
</tr>
<tr>
<td>'98</td>
<td>7.0</td>
<td>0.4</td>
</tr>
<tr>
<td>'00</td>
<td>7.6</td>
<td>0.5</td>
</tr>
<tr>
<td>'02</td>
<td>9.2</td>
<td>0.5</td>
</tr>
<tr>
<td>'04</td>
<td>10.1</td>
<td>0.5</td>
</tr>
<tr>
<td>'06</td>
<td>11.3</td>
<td>0.5</td>
</tr>
<tr>
<td>'08</td>
<td>13.2</td>
<td>0.5</td>
</tr>
<tr>
<td>'10</td>
<td>13.8</td>
<td>0.5</td>
</tr>
</tbody>
</table>

- **97.7%** Percentage surviving between 2003 and 2006
- **60,220** Estimated new cases in 2013
- **3.6%** Percentage of all new cancer diagnoses
- **1,850** Estimated deaths in 2013
- **0.3%** Percentage of all cancer deaths

*Source: National Cancer Institute*

### High Frequency/Low Mortality

- Papillary (Adeno)carcinoma = 8260/3
- Follicular (Adeno)carcinoma = 8330/3

### Low Frequency/High Mortality

- Medullary Carcinoma
- Anaplastic Carcinoma

Papillary-Follicular Adenocarcinoma = 8340/3
PRINCIPLES OF THYROID STIMULATING HORMONE (TSH) SUPPRESSION

- Because TSH is a trophic hormone that can stimulate the growth of cells derived from thyroid follicular epithelium, the use of levothyroxine to maintain low TSH levels is considered optimal in treatment of patients with papillary, follicular, or Hürthle cell carcinoma. However, data are lacking to permit precise specification of the appropriate serum levels of TSH.

- In general, patients with known residual carcinoma or at high risk for recurrence should have TSH levels maintained below 0.1 mU/L, whereas disease-free patients at low risk for recurrence should have TSH levels maintained either slightly below or slightly above the lower limit of the reference range.

- For low-risk patients with biochemical evidence but no structural evidence of disease (eg, Tg positive, but imaging negative), maintain TSH levels at 0.1 - 0.5 mU/L.

- Patients who remain disease free for several years can probably have their TSH levels maintained within the reference range.

- Given the potential toxicities associated with TSH-suppressive doses of levothyroxine—including cardiac tachyarrhythmias (especially in the elderly) and bone demineralization (particularly in post-menopausal women) as well as frank symptoms of thyrotoxicosis—the risk and benefit of TSH-suppressive therapy must be balanced for each individual patient.

- Patients whose TSH levels are chronically suppressed should be counseled to ensure adequate daily intake of calcium (1200 mg/day) and vitamin D (1000 units/day).
Recent Developments in Cancer Diagnosis and Treatment

FCDS ANNUAL CONFERENCE
ORLANDO, FL
7/25/2014

STEVEN PEACE, CTR
Outline

- Introduction
- Trends in Cancer Incidence and Mortality
- Current Trends in Cancer Screening
- The Over-Diagnosis and Over-Treatment of “Cancer”
- Canadian National Breast Screening Study – 25 Year Follow-up
- Surgeon General’s Report on Smoking and Health – 50 Years
- The State of Cancer Care in America – 2014
- This and That
- Wrap Up
Early-detection via screening identifies early cancers (non-invasive, minimally invasive, in-situ) amenable to treatment.

Early-treatment should focus on prevention and lifestyle with focus on smoking cessation, weight control, and active lifestyle.

The 2 biggest risk factors for all cancers: Smoking & Obesity

Obesity is related to diet AND exercise and causes diabetes

Obesity-related diabetes is linked to increases in occurrence of cancers of the esophagus, thyroid, pancreas, gallbladder, kidney, colon, female breast (post-menopausal) and endometrium.

Source: Cancer Research, American Association for Cancer Research
Demographic Changes in U.S. Population – age, race, income, insurance
Trends in Smoking, HPV Infection, Obesity, Nutrition, Diabetes, Physical Activity
Trends in Cancer Screening and Prevention
Trends in Cancer Diagnosis and Treatment

Source: Cancer Research, American Association for Cancer Research
Estimates suggest that 25%-30% of individuals classified as “cancer survivors” never needed any treatment for their cancer.

- 20% of image-detected lung cancers
- 25% of mammography-detected breast cancers
- 40% of ultrasound-detected thyroid cancers
- 60% of PSA-detected prostate cancers

Early non-invasive cancers are not malignant by definition and cannot spread or metastasize if treated with surgical resection.

Patients may develop new cancers, but non-invasive cancers will not “recur” in surgically treated site – optimal care – prevention

Non-invasive cancers often grouped with and treated as if they were invasive cancers – tied to reimbursement / patient choice

Source: 2014 Cancer Facts & Figures and Dr. Otis Brawley
Once diagnosed – patients’ and their families hear the word “cancer” they naturally want to eradicate any trace of cancer in themselves or their family member. So, they agree to or even insist on cancer treatment that may do more harm than good to the patient/cancer.

Should all screen-detected neoplasms deemed non-invasive be classified, treated, and followed as though they were malignant?

What is the cost associated with over-treatment?
What are the risks associated with over-treatment?

What should screening and treatment recommendations include?
What else can be done by patient’s and health care providers?

Source: 2014 Cancer Facts & Figures and Dr. Otis Brawley
Surgeon General Report on Smoking & Health

Source: American Association for Cancer Research – AACR.org/Surgeon General
<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
<th>Approved Use</th>
<th>Precision or Targeted Therapy?</th>
<th>Oral or Injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sorafenib</td>
<td>NEXAVAR</td>
<td>Differentiated thyroid carcinoma</td>
<td>N</td>
<td>Oral</td>
</tr>
<tr>
<td>Crizotinib</td>
<td>Xalkori</td>
<td>Non-small cell lung cancer, anaplastic lymphoma kinase (ALK)-positive</td>
<td>Y</td>
<td>Oral</td>
</tr>
<tr>
<td>Ibrutinib</td>
<td>IMBRUVICA</td>
<td>Mantle cell lymphoma</td>
<td>Y</td>
<td>Oral</td>
</tr>
<tr>
<td>Obinutuzumab</td>
<td>GAZYVA</td>
<td>Chronic lymphocytic leukemia</td>
<td>Y</td>
<td>Injection</td>
</tr>
<tr>
<td>Pertuzumab injection</td>
<td>PERJETA</td>
<td>HER2-positive breast cancer</td>
<td>Y</td>
<td>Injection</td>
</tr>
<tr>
<td>Paclitaxel protein-bound particles (albumin-bound)</td>
<td>Abraxane for injectable suspension</td>
<td>Adenocarcinoma of the pancreas</td>
<td>N</td>
<td>Injection</td>
</tr>
<tr>
<td>Afatinib</td>
<td>Gilotrif tablets</td>
<td>Non-small cell lung cancer, with epidermal growth factor receptor (EGFR) mutations</td>
<td>Y</td>
<td>Oral</td>
</tr>
<tr>
<td>Denosumab</td>
<td>Xgeva injection</td>
<td>Giant cell tumor of bone</td>
<td>N</td>
<td>Injection</td>
</tr>
<tr>
<td>Lenalidomide capsules</td>
<td>REVUMID</td>
<td>Mantle cell lymphoma</td>
<td>N</td>
<td>Oral</td>
</tr>
<tr>
<td>Trametinib</td>
<td>MEKINST tablet</td>
<td>Melanoma with BRAF V600E or V600K mutation</td>
<td>Y</td>
<td>Oral</td>
</tr>
<tr>
<td>Dabrafenib</td>
<td>TAFINLAR capsule</td>
<td>Melanoma with BRAF V600E mutation</td>
<td>Y</td>
<td>Oral</td>
</tr>
<tr>
<td>Radium Ra 223 dichloride</td>
<td>Xofigo Injectio</td>
<td>Prostate cancer</td>
<td>N</td>
<td>Injection</td>
</tr>
<tr>
<td>Erlotinib</td>
<td>Tarceva</td>
<td>Non-small cell lung cancer with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations</td>
<td>Y</td>
<td>Oral</td>
</tr>
<tr>
<td>Ado-trastuzumab emtansine</td>
<td>KADCYLA for injection</td>
<td>HER2-positive, metastatic breast cancer</td>
<td>Y</td>
<td>Injection</td>
</tr>
<tr>
<td>Pomalidomide</td>
<td>POMALYST capsules</td>
<td>Multiple myeloma</td>
<td>N</td>
<td>Oral</td>
</tr>
<tr>
<td>Doxorubicin hydrochloride liposome injection</td>
<td>Generic version of DOXIL Injection</td>
<td>Ovarian cancer</td>
<td>N</td>
<td>Injection</td>
</tr>
<tr>
<td>Doxorubicin hydrochloride liposome injection</td>
<td>Generic version of DOXIL Injection</td>
<td>AIDS-related Kaposi’s sarcoma</td>
<td>N</td>
<td>Injection</td>
</tr>
<tr>
<td>Bevacizumab</td>
<td>Avastin</td>
<td>Colorectal cancer</td>
<td>N</td>
<td>Injection</td>
</tr>
</tbody>
</table>
2014 FCDS Annual Conference - Recordings & Handouts

http://fcds.med.miami.edu/inc/educationtraining.shtml

Day 1

- All the Slides/Handouts/PDFs from the Annual Meeting in one zip file
- Agenda
- Welcome to the FCDS Annual Meeting
- FCDS Updates - State of the State, Dr. Jill MacKinnon, Slides, Recording
- Cancer Data Uses and Dissemination, Joseph Lowry, MPH, Slides, Recording
- Individual and Neighborhood-Level Predictors of Mortality In Florida Colorectal Cancer Patients, Dr. David Lee, Slides, Recording
- Patterns of Care - Initial Assessment of Adherence to Evidence-Based Cancer Treatment Guidelines - Colon, Dr. Monique Hernandez and Judy Bonner, MSN, CTR, Slides, Recording
- SART Data Linkage, Brad Wohler, Slides, Recording
- Highlights from the NAACCR 2014 Annual Conference, Dr. Jill MacKinnon, Slides, Recording
- Update on Meaningful Use Stage II and CDA Validation, Dr. Monique Hernandez, Slides, Recording
- Data Acquisition Update, Mike Thiry, Slides, Recording
- Transition from CSV2 to Direct-Coded TNM and Summary Stage, Dr. Jill MacKinnon, Recording only, no slides with this session
- 2014 Reporting Requirements - 2014 FCDS DAM Highlights, Steve Peace, Slides, Recording
- 2014-2015 FCDS Education and Training Plan, Steve Peace, Slides, Recording
- Physician Claims and Treatment Data Validation Study, Dr. Monique Hernandez, Slides, Recording
- Introducing the FCDS IDEA Follow-Up System, Gary Levin, Kelly King, CTR, Cleveland Clinic, Sara Holton, CTR, Mayo Clinic, Slides, Slides (Sara Holton), Recording
- 2014 FCDS Data Validation Audit - 2012 Dx, Steve Peace, Slides, Recording
- Joan Byers Award Presentation, Mike Thiry, Slides, Recording
- The FCDS Annual Meeting of the Future and Round Table Discussion, Dr. Jill MacKinnon, Slides, Recording

Day 2

- 2013 FCDS QC Activities Summary, Steve Peace, Slides, Recording
- 2014 Grade Coding Instructions and ICD-O-3 Updates, Steve Peace, Slides, Recording
- 2014 Hematopoietic Rules and Data Base Updates, Steve Peace, Slides, Recording
- Coding Instructions for Surgery Fields Including Scope Rag LN, Steve Peace, Slides, Recording
- Recurring Issues and Problem Areas for Florida Registrars, Steve Peace, Slides, Recording
- Recent Developments in Cancer Diagnosis and Treatment, Steve Peace, Slides, Recording

Handouts

- Cancer Surveillance Community Timeline As of June 9, 2014
- Collaborative Stage Data Collection System Coding Instructions
- Installation Instructions Collaborative Stage Coding Instructions v02.05
- Free TNM 7th Edition Webinar Series Recordings and Other Resources
- FCDS Data Quality Indicator Report
- Guidelines for ICD-O-3 update implementation Effective January 1, 2014
- Users Guide for NCI’s Online Hematopoietic and Lymphoid Database
- Instructions for Coding Grade for 2014+
- FCDS DAM LVI Errata
- Scope of Regional Lymph Node Surgery: A review of Data Validity, Revised Coding Directives, and Agency Transition Plans
Education & Training

Log CEUs with FCDS - starting with the FCDS Educational webcast series on 8/21/2014, you can use this page to log FCDS webinars you have viewed live or later via recordings on this page. Only certain webinars are logged. NAACCR webinars have their own CEU recording mechanism.
FCDS offers many webinars throughout the year. These webinars are recorded and can be used to earn NCRA CEUs. This screen will record your attendance information with FCDS. Should your facility be audited, FCDS can examine this attendance information and provide you with a summary.

First Name: 
Middle: 
Last Name: 
Credentials: 
Title: 
Organization: 
Address: 
Address: 
City: 
State: 
Zip: 
Phone: 
Fax: 
Email (required): 

When did you attend/view the webinar recording MM/DD/YYYY:

- 08/21/2014, 2014 Reporting Requirements: FCDS Annual Meeting Highlights, 2 CEUs
- 09/18/2014, GYN Neoplasms, 2 CEUs
- 10/16/2014, Neuroendocrine Tumors (NET) and GI Stromal Tumors (GIST), 2 CEUs
- 11/20/2014, Reportable Skin Cancers, 2 CEUs
- 01/15/2015, Genitourinary Neoplasms (Kidney, Bladder, Prostate), 2 CEUs
- 02/19/2015, Lower GI Tract Neoplasms, 2 CEUs

Press to submit this information to FCDS
Wrap Up